

The role of forkhead box M1-methionine adenosyltransferase 2 A/2B axis in liver inflammation and fibrosis

Received: 22 September 2023

Accepted: 9 September 2024

Published online: 27 September 2024



Bing Yang^{1,2,12}, Liqing Lu^{1,3,12}, Ting Xiong^{1,4,12}, Wei Fan¹, Jiaohong Wang¹, Lucía Barbier-Torres¹, Jyoti Chhimwal¹, Sonal Sinha¹, Takashi Tsuchiya¹, Nirmala Mavila¹, Maria Lauda Tomasi¹, DuoYao Cao⁵, Jing Zhang^{1,6}, Hui Peng¹, José M. Mato⁷, Ting Liu⁸, Xi Yang², Vladimir V. Kalinichenko^{9,10}, Komal Ramani¹, Jenny Han^{1,11}, Ekihiro Seki¹, Heping Yang¹✉ & Shelly C. Lu¹✉

Methionine adenosyltransferase 2 A (MAT2A) and MAT2B are essential for hepatic stellate cells (HSCs) activation. Forkhead box M1 (FOXM1) transgenic mice develop liver inflammation and fibrosis. Here we examine if they crosstalk in male mice. We found FOXM1/MAT2A/2B are upregulated after bile duct ligation (BDL) and carbon tetrachloride (CCl₄) treatment in hepatocytes, HSCs and Kupffer cells (KCs). FDI-6, a FOXM1 inhibitor, attenuates the development and reverses the progression of CCl₄-induced fibrosis while lowering the expression of FOXM1/MAT2A/2B, which exert reciprocal positive regulation on each other transcriptionally. Knocking down any of them lowers HSCs and KCs activation. Deletion of FOXM1 in hepatocytes, HSCs, and KCs protects from BDL-mediated inflammation and fibrosis comparably. Interestingly, HSCs from *Foxm1*^{Hep-/-}, hepatocytes from *Foxm1*^{HSC-/-}, and HSCs and hepatocytes from *Foxm1*^{KC-/-} have lower FOXM1/MAT2A/2B after BDL. This may be partly due to transfer of extracellular vesicles between different cell types. Altogether, FOXM1/MAT2A/MAT2B axis drives liver inflammation and fibrosis.

Hepatic fibrosis is characterized by the accumulation of extracellular matrix (ECM) components such as collagens type I (COL1A1) and type III, which may further lead to cirrhosis and liver cancer¹. Activation of hepatic stellate cells (HSCs) is a crucial event in liver fibrosis. Forkhead box M1 (FOXM1) is a member of the forkhead box family with winged helix DNA binding domain that works as a crucial transcription factor in proliferation and oncogenesis^{2,3}. Recent studies have reported that FOXM1 could promote multiple organ fibrosis including liver fibrosis^{4–6}. Furthermore, Kurahashi et al.³ demonstrated that over-expression of FOXM1 in hepatocytes caused spontaneous liver injury, inflammation, fibrosis, and hepatocellular carcinoma (HCC). Forkhead domain inhibitory-6 (FDI-6), a small molecule that selectively targets the FOXM1 DNA-binding domain, could inhibit the transcription of FOXM1 target genes⁷. FDI-6 inhibited corneal inflammation and fibrosis

after alkali burn in rats⁸ and attenuated subconjunctival fibrosis in a trabeculectomy rabbit model⁹. These studies suggest that targeting FOXM1 may be a potential therapeutic strategy in liver inflammation and fibrosis. However, this has not been examined.

Methionine adenosyltransferase (MAT) is an essential enzyme that catalyzes the biosynthesis of S-adenosylmethionine (SAME)¹⁰. *MAT2A* encodes for the α 2 catalytic subunit and *MAT2B* gene encodes the β regulatory subunit of the MATII isoenzyme¹⁰. MAT2A and MAT2B are expressed in extrahepatic tissues and non-parenchymal cells of the liver, such as HSCs and Kupffer cells (KCs)¹¹. MAT2A expression is induced in cultured activated HSCs, and in livers treated with carbon tetrachloride (CCl₄) or thioacetamide (TAA)¹². MAT2A and MAT2B affect HSCs activation through changes in SAME levels and extracellular-regulated kinase and phosphoinositide 3-kinase signaling

mechanisms¹⁰. In addition, *MAT2B* siRNA treatment reduced collagen level and inhibited HSCs activation in TAA-induced liver fibrosis in mice¹³. Wang et al.¹⁴ also found that knockdown of *MAT2A* alleviated CCl₄ and transforming growth factor-beta 1 (TGF-β1)-induced HSCs activation, whereas overexpression of *MAT2A* facilitated hepatic fibrosis. Here we investigated whether there is a crosstalk between FOXM1, *MAT2A* and *MAT2B*; to better understand the role of FOXM1 in a cell-type specific manner, we established *Foxm1*^{Hep-/-}, *Foxm1*^{HSC-/-}, and *Foxm1*^{KC-/-} mice and examined the role of the FOXM1/*MAT2A*/*MAT2B* axis in vitro and vivo.

In this work, we found that FOXM1, *MAT2A* and *MAT2B* expression are upregulated in hepatocytes, HSCs, and KCs after bile duct ligation (BDL) in mice. Treatment with FDI-6 significantly attenuates the development of liver injury and fibrosis but more remarkably, reverses liver fibrosis that was already established. We found FOXM1, *MAT2A* and *MAT2B* directly interact, and they positively regulate each other at the transcriptional level via FOX elements present in their promoters. Knocking down any of the three inhibits TGF-β1-induced HSCs activation as well as lipopolysaccharide (LPS)-induced macrophage activation. Interestingly, deleting FOXM1 from hepatocytes, HSCs or KCs all protect from liver injury and fibrosis induced by BDL comparably. This may be in part due to exchange of FOXM1, *MAT2A* and *MAT2B* in secreted extracellular vesicles (EVs) amongst the different cell types. Taken together, our results suggest targeting any of the components of the FOXM1/*MAT2A*/*MAT2B* axis may be a potential therapeutic strategy in liver fibrosis.

Results

FOXM1/*MAT2A*/*MAT2B* axis is induced in liver fibrosis

MAT2A, *MAT2B* and FOXM1 are involved in liver fibrosis^{3,13,14}. Here we found the upregulation of FOXM1, *MAT2A* and *MAT2B* in hepatic cells and small bile ducts in human and murine fibrotic livers (Supplementary Fig. 1a–e). Hepatocytes express lower levels of *Mat2a* and *Mat2b* as compared to HSCs and KCs at baseline, but they are more induced following BDL and CCl₄ treatments (Supplementary Fig. 1e). Interestingly, *Foxm1* was expressed at a lower level in HSCs than in hepatocytes and KCs but it was induced in all three cell types after BDL and CCl₄ treatment (Supplementary Fig. 1e). These proteins are also induced in primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) (Supplementary Fig. 2a–c). Furthermore, FOXM1 expression increased from day 1 to day 14 after bile duct ligation (BDL) while expression of *MAT2A* and *MAT2B* increased from day 2 to day 14 after BDL (Fig. 1a), suggesting FOXM1 may be upstream of *MAT2A* and *MAT2B*. Primary HSCs isolated from BDL mice at day 7 showed higher cytoplasmic and nuclear FOXM1, *MAT2A*, and *MAT2B* staining compared with sham control (Fig. 1b). FDI-6 treatment reduced the mRNA and protein levels of FOXM1, *MAT2A*, and *MAT2B* in the day-5 culture activated HSCs and LX-2 cell line (Fig. 1c, d, densitometry is shown in Supplementary Fig. 3a, b). FDI-6 also reduced cytoplasmic and nuclear staining of FOXM1, *MAT2A*, and *MAT2B* in LX-2 cells (Fig. 1e), and in BDL livers (Fig. 1f, densitometry is shown in Supplementary Fig. 3c, d). FDI-6 also lowered the proliferation (Fig. 1g) and migration (Fig. 1h) of LX-2 cells.

FDI-6 in the development and progression of liver fibrosis


To examine how inhibiting FOXM1 will impact on CCl₄-induced liver fibrosis, we divided the mice into two groups (prevention and treatment). In the prevention group, FDI-6 was administered from the start of CCl₄ treatment for three weeks. In the treatment group, FDI-6 was started after liver fibrosis was already established (after three weeks of CCl₄) and continued with CCl₄ for two additional weeks. In these two groups, immunohistochemistry (IHC) showed that FDI-6 treatment reduced the expression of COL1A1, F4/80, α-SMA, FOXM1, *MAT2A*, and *MAT2B* induced by CCl₄ (Fig. 2a). FDI-6 also reduced the levels of alanine transaminase (ALT), aspartate transferase (AST), and hydroxyproline induced by CCl₄ (Fig. 2b–d). Furthermore, FDI-6 reduced the mRNA

(Fig. 2e) and protein levels (Fig. 2f, densitometry is shown in Supplementary Fig. 3e) of FOXM1, *MAT2A*, *MAT2B*, α-SMA, F4/80, and COL1A1. Note that FDI-6 lowered fibrosis markers such as hydroxyproline and COL1A1 to below the levels seen with CCl₄ alone for three weeks, which suggests it can reverse already existing fibrosis. CCl₄ treatment also increased the interaction between FOXM1 and *MAT2B*, which was reduced by FDI-6 (Supplementary Fig. 3f, g).

Reciprocal positive regulation between FOXM1/*MAT2A*/*MAT2B*

To better understand how they crosstalk, we examined the relationship between FOXM1 and *MAT2A*/*MAT2B* in LX-2 cells and primary cholangiocytes isolated from BDL livers. FOX binding sites are present in the human *MAT2A* (Supplementary Fig. 4a), *MAT2B* (Supplementary Fig. 4b), and *FOXM1* promoter regions (Supplementary Fig. 5). Different fragments of these human promoter constructs were transfected in LX-2 cells and primary cholangiocytes and treatment with FDI-6 (5 μM) or FOXM1 siRNA significantly decreased *MAT2A* promoter activity with maximal effect seen with promoter fragment –271/+60 in LX-2 cells (Fig. 3a, left), *MAT2B* promoter activity with maximal effect seen with fragment –250/+3 (Fig. 3b, left), and *FOXM1* promoter –1333/+107 fragment (Fig. 3c, left). Similar attenuation was seen in all three promoters in primary cholangiocytes after these treatments (Fig. 3a, right for *Mat2a*, Fig. 3b, right for *Mat2b*, Fig. 3c, right for *Foxm1*), suggesting important elements are within those regions of the *MAT2A*/*MAT2B*/*FOXM1* promoters. Mutation at each of the FOX binding sites significantly attenuated the ability of FDI-6 and FOXM1 siRNA treatments to lower *MAT2A*/*MAT2B*/*FOXM1* promoter activities (Fig. 3d–f). These results show that FOXM1 regulates *MAT2A*, *MAT2B*, and *FOXM1* mainly via FOX binding sites.

Since we found interaction between FOXM1, *MAT2A*, and *MAT2B* in liver lysates (Supplementary Fig. 3f), we next examine if they interact at the two FOX binding sites of the *FOXM1* promoter using chromatin immunoprecipitation (ChIP) and sequential ChIP (Seq-ChIP). We found that FOXM1 but not *MAT2A* or *MAT2B* can bind to the FOX region (Fig. 3g). However, in the presence of FOXM1, *MAT2A* and *MAT2B* co-occupy this region on Seq-ChIP (Fig. 3g). Furthermore, *MAT2A*, *MAT2B*, and *FOXM1* overexpression (OV) led to an increase in FOXM1 and *MAT2A*/*MAT2B* binding and the opposite was true with *MAT2A*, *MAT2B*, and *FOXM1* knockdown in LX-2 cells (Fig. 3g, h). FDI-6 treatment had the same results as FOXM1, *MAT2A* and *MAT2B* knockdown in LX-2 cells and cholangiocytes (Supplementary Fig. 6a, b). To confirm that these proteins were binding to the FOX element, we used electrophoretic mobility shift assay (EMSA), which confirmed that FOXM1, *MAT2A* and *MAT2B* siRNAs decreased and their overexpression increased protein binding to the FOX elements (Fig. 3i). Recombinant protein (r) of *MAT2A* or *MAT2B* cannot bind to the FOX element by itself. However, they can bind when combined with rFOXM1 as shown by supershift assay (Fig. 3j). Using co-immunoprecipitation (Co-IP) with purified recombinant proteins we found direct interaction between FOXM1 and *MAT2A* and *MAT2B* (Fig. 3k), and BDL increased their interaction in the liver (Fig. 3l). These results suggest these three proteins all interact at the FOX elements to activate the transcription of each other. Consistently, primary cholangiocytes isolated from BDL and sham control livers showed BDL increased cytoplasmic and nuclear FOXM1, *MAT2A* and *MAT2B* content (Supplementary Fig. 6c). Furthermore, FOXM1, *MAT2A*, and *MAT2B* overexpression increased each other's protein expression and mRNA levels in LX-2 cells (Supplementary Fig. 7a), and the opposite was true with FOXM1, *MAT2A*, and *MAT2B* knockdown (Supplementary Fig. 7b). Consistent with the importance of FOXM1/*MAT2A*/*MAT2B* in HSCs activation, their siRNAs inhibited while overexpression raised migration of LX-2 cells (Supplementary Fig. 8). Lastly, FOXM1 (Supplementary Fig. 9a), *MAT2A* (Supplementary Fig. 9b) and *MAT2B* (Supplementary Fig. 9c) mRNA levels are all elevated in human liver cirrhosis (*n* = 31) and they positively correlate with each other (Supplementary Fig. 9d–f). Their high expressions in liver



cirrhosis correlates with hepatitis B virus (HBV) infection (Supplementary Table 1).

Foxm1^{Hep-/-} mice have lower BDL-induced injury and fibrosis

Hepatocellular injury is a central mechanism of inflammation and disease progression in chronic liver diseases¹⁵. Hepatocytes, activated

HSCs, and KCs cooperate in the establishment and resolution of liver fibrosis¹⁶. To explore how hepatocytes' FOXM1 is involved in liver fibrosis, we generated *Foxm1*^{Hep-/-} mice (Supplementary Fig. 10a). *Foxm1*^{Hep-/-} mice subjected to BDL have lower CK19 (biliary/progenitor cell marker), α -SMA (a biomarker for myofibroblast differentiation), F4/80 (a marker of macrophages) and Sirius red staining (Fig. 4a, b),

Fig. 1 | Expression of FOXM1/MAT2A/MAT2B during bile duct ligation (BDL) and after FDI-6 treatment. **a** Western blots show the time course of protein expression of FOXM1, MAT α 2, and MAT2 β in liver tissues after BDL ($n = 3$ independent experiments). **b** Immunofluorescence (IF) of FOXM1, MAT α 2, and MAT2 β in primary hepatic stellate cells (HSCs) isolated from sham and BDL mice at day 5. The top row shows DAPI staining. The second and third rows show the antibody (AB) staining. The fourth row shows merged images of DAPI and FOXM1, MAT α 2 or MAT2 β , and the fifth row shows high magnification (HM) from the merged image ($n = 3$ independent experiments). **c** Expression of mRNA (top) and protein (bottom) of FOXM1, MAT α 2, MAT2 β , α -SMA, and COL1A1 in HSCs isolated from WT mice and cultured for up to 5 days and FDI-6 treatment for 24 h starting at day 4. Data presented as mean $\pm$ SEM ($n = 3$ per group), mRNA levels of *Foxm1*, *Mat2a*, *Mat2b*, *Acta2* and *Col1a1* in HSCs at day 5 vs. day 1, $p = 0.0044$, $p = 0.0029$, $p = 0.0056$, $p = 0.0010$ and $p = 0.00002$, respectively. mRNA levels of *Foxm1*, *Mat2a*, *Mat2b*, *Acta2* and *Col1a1* in HSCs at day 5 + FDI-6 vs. day 1, $p = 0.0431$, $p = 0.0152$, $p = 0.0245$, $p = 0.0083$, and $p = 0.0082$, respectively. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$. See Supplementary Fig. 3a for densitometric values of

the western blots. **d** Expression of mRNA and protein of FOXM1, MAT α 2, MAT2 β , α -SMA, and COL1A1 after FDI-6 treatment in LX-2 cells. Data presented as mean $\pm$ SEM ($n = 3$ per group), mRNA levels of *Foxm1*, *Mat2a*, *Mat2b*, *Acta2* and *Col1a1* in LX-2 cells with DMSO treatment vs. FDI-6, $p = 0.0187$, $p = 0.0023$, $p = 0.0122$, $p = 0.0108$ and $p = 0.0124$, respectively. * $p < 0.05$, ** $p < 0.01$ vs. DMSO. See Supplementary Fig. 3b for densitometric values of the western blots. **e** IF of LX-2 cells after treatment with FDI-6. HM, high magnification from the merged images ($n = 3$ independent experiments). **f** FOXM1, MAT α 2, and MAT2 β in cytoplasm and nucleus from HSCs isolated from sham and BDL mice with or without FDI-6 treatment ($n = 3$ independent experiments). Densitometry for cytoplasmic protein levels is summarized in Supplementary Fig. 3c and nuclear protein levels is summarized in Supplementary Fig. 3d. Proliferation (**g**) and migration (**h**) of LX-2 cells in vitro after FDI-6 treatment for 24 h. Data presented as mean $\pm$ SEM ($n = 3$ per group). $p = 0.00016$, $p = 0.00002$ vs. DMSO. Statistical significance was determined by using two-tailed unpaired Student's *t*-test. *** $p < 0.001$, **** $p < 0.0001$ vs. DMSO ($n = 3$). Abbreviations: BDL bile duct ligation, DMSO dimethylsulfoxide. Source data are provided as a Source Data file.

hydroxyproline (Fig. 4c), ALT (Fig. 4d), and AST (Fig. 4e) levels, lower F4/80 positive cells (Fig. 4f), CK19 and α -SMA area/total area (Fig. 4g) as compared to Flox controls after BDL. We next measured the expression levels of FOXM1, MAT α 2 and MAT2 β in a cell-type specific manner from *Foxm1*^{Hep-/-} mice at baseline and after BDL. *Foxm1* mRNA and protein are not detected in hepatocytes or cholangiocytes (Fig. 4h–j). *Foxm1*^{Hep-/-} mice have reduced protein and mRNA levels of *Mat2a*, and *Mat2b* in hepatocytes (Fig. 4h, i), cholangiocytes (Fig. 4h–j), and HSCs (Fig. 4h–k) after BDL but unchanged in KCs (Fig. 4h–l) as compared to Flox controls after BDL. See Supplementary Fig. 11a–d for a summary of densitometric changes of Fig. 4h.

Foxm1^{HSC-/-} mice have lower BDL-induced injury and fibrosis

Activated HSCs release ECM, which is considered a key event in liver fibrosis. To better understand the role of HSCs FOXM1 in liver fibrosis, we generated *Foxm1*^{HSC-/-} mice (Supplementary Fig. 10b). IHC results showed *Foxm1*^{HSC-/-} mice have lower α -SMA and Sirius Red staining (Fig. 5a, b) and hydroxyproline level (Fig. 5c) after BDL, but F4/80 and CK19 staining were similar to Flox controls after BDL (Fig. 5a). ALT (Fig. 5d) and AST (Fig. 5e) levels were lower, F4/80 positive number (Fig. 5f) and CK19 area/total area (Fig. 5g) were similar but α -SMA area/total area was lower than Flox controls after BDL (Fig. 5g). FOXM1 protein (Fig. 5h) and mRNA (Fig. 5k) in HSCs after BDL are undetectable from *Foxm1*^{HSC-/-}. *Foxm1*^{HSC-/-} mice have lower FOXM1, MAT α 2 and MAT2 β protein (Fig. 5h) and mRNA (Fig. 5i) levels in hepatocytes as compared to Flox controls after BDL but cholangiocytes (Fig. 5h–j) and KCs (Fig. 5h–l) were similar. See Supplementary Fig. 11e–h for a summary of densitometric changes of Fig. 5h.

Foxm1^{KC-/-} mice have lower BDL-induced injury and fibrosis

KCs are resident macrophages that are localized within the lumen of the liver sinusoids, which play a vital role in liver inflammation¹⁶. In response to hepatocyte injury, KCs become activated and express cytokines and signaling molecules, such as tumor necrosis factor α (TNF- α), interleukin-1 β (IL-1 β), and interleukin-6 (IL-6)¹⁶. To examine the role of macrophage-derived FOXM1, we created *Foxm1*^{KC-/-} mice (Supplementary Fig. 10c). IHC results showed *Foxm1*^{KC-/-} mice have lower F4/80, Sirius red, and α -SMA staining after BDL but no change in CK19 staining (Fig. 6a, b, f, g). They have lower levels of hydroxyproline (Fig. 6c), ALT (Fig. 6d) and AST (Fig. 6e). FOXM1 protein (Fig. 6h) and mRNA (Fig. 6i) in KCs after BDL are undetectable in *Foxm1*^{KC-/-} mice. However, *Foxm1*^{KC-/-} mice have lower protein (Fig. 6h) and mRNA level of *Foxm1*, *Mat2a*, and *Mat2b* in hepatocytes (Fig. 6i) and HSCs (Fig. 6k) as compared to Flox controls after BDL, except for cholangiocytes (Fig. 6j), which were similar. See Supplementary Fig. 12a–d for a summary of densitometric changes of Fig. 6h.


FOXM1-MAT2A-MAT2B interplay drives fibrosis and inflammation

TGF- β 1 promotes liver fibrosis by activating HSCs¹⁷. SMAD3 is the core transcription factor that mediates TGF- β signaling¹⁸. To see if MAT2A and MAT2B are important in FOXM1-driven fibrosis, we treated LX-2 cells with TGF- β 1 (20 ng/ml) and found FOXM1, MAT α 2, MAT2 β and p-SMAD3 levels were increased three hours after treatment, along with an increase in fibrosis markers such as α -SMA and COL1A1 (Fig. 7a, see Supplementary Fig. 12e for densitometric changes). Knocking down *FOXM1*, *MAT2A*, or *MAT2B* reduced protein expression of MAT α 2, MAT2 β , SMAD3, p-SMAD3, α -SMA and COL1A1 (Fig. 7b, see Supplementary Fig. 12f for densitometric changes). To determine the effect of the FOXM1/MAT2A/MAT2B axis on TGF- β 1-mediated HSC activation, we treated the LX-2 cells with *MAT2A* siRNA plus TGF- β 1 or *MAT2B* siRNA plus TGF- β 1. Knocking down either *MAT2A* or *MAT2B* attenuated TGF- β 1-mediated induction of FOXM1, MAT α 2, MAT2 β , SMAD3, p-SMAD3, α -SMA and COL1A1. *FOXM1* overexpression further augmented TGF- β 1-induced protein expression of MAT α 2, MAT2 β , SMAD3, p-SMAD3, α -SMA and COL1A1, but not if *MAT2A* or *MAT2B* were silenced (Fig. 7c, see Supplementary Fig. 13a for densitometric changes). These results indicate the FOXM1/MAT2A/MAT2B axis is important in liver fibrosis induced by the TGF- β 1 signaling pathway and MAT2A and MAT2B are required for FOXM1 to exert its pro-fibrogenic effect.

Macrophages have emerged as the central players in sustaining and amplifying chronic inflammation, which is the hallmark of liver fibrosis¹⁹. Lipopolysaccharide (LPS) stimulates RAW 264.7 macrophages to release pro-inflammatory activation, such as TNF- α and IL-6²⁰. We next examined the FOXM1/MAT2A/MAT2B axis in inflammation, first using RAW 264.7 cells, and then confirming the results in primary KCs. Interestingly, knocking down *FOXM1*, *MAT2A* or *MAT2B* reduced the protein expression of FOXM1, MAT α 2, MAT2 β , TNF- α , and IL-6 at baseline and attenuated or completely blocked LPS-induced expression of these proteins (Fig. 7d, see Supplementary Fig. 13b for densitometric changes). Importantly, *FOXM1* overexpression recapitulated the effects of LPS on TNF- α , and IL-6 but silencing *MAT2A* or *MAT2B* significantly attenuated FOXM1-mediated induction (Fig. 7e, see Supplementary Fig. 13c, d for densitometric changes). Silencing *Foxm1*, *Mat2a* or *Mat2b* attenuated LPS-induced TNF- α , and IL-6 release (Supplementary Fig. 13e). These results indicate the FOXM1/MAT2A/MAT2B axis also participates in inflammation.

Liver cells secrete EVs containing FOXM1/MAT α 2/MAT2 β

To understand why HSCs from *Foxm1*^{Hep-/-}, hepatocytes from *Foxm1*^{HSC-/-} and HSCs and hepatocytes from *Foxm1*^{KC-/-} all have lower levels of FOXM1, MAT α 2 and MAT2 β after BDL, we examined the possibility that



these proteins are secreted in EVs and transferred to other cells. First, we isolated and cultured hepatocytes, HSCs, and KCs from WT and their respective KO at day 14 of BDL. The following day EVs were isolated from culture medium and used to treat KO HSCs or hepatocytes with the following combinations: 1. HSCs from *Foxm1*^{HSC-/-} treated with EVs from hepatocytes of WT and *Foxm1*^{Hep-/-}, 2. hepatocytes from *Foxm1*^{Hep-/-}

treated with EVs from HSCs of WT and *Foxm1*^{HSC-/-}, 3. HSCs from *Foxm1*^{HSC-/-} treated with EVs from KCs of WT and *Foxm1*^{KC-/-}, and 4. hepatocytes from *Foxm1*^{Hep-/-} treated with EVs from KCs of WT and *Foxm1*^{KC-/-}. We found cells treated with EVs from cell-type specific knockouts all resulted in lower expression of FOXM1, MATα2, and MAT2β as compared to cells treated with EVs from WT cells after BDL

Fig. 2 | Prevention and treatment roles of FDI-6 in carbon tetrachloride (CCl₄)-induced liver fibrosis. **a** Liver sections from prevention groups of the corn oil (Oil) + DMSO, Oil + FDI-6, CCl₄ + DMSO, and CCl₄ + FDI-6 for three weeks, and treatment groups of Oil + DMSO, Oil + FDI-6, CCl₄ + DMSO, and CCl₄ + FDI-6 treated for two weeks after CCl₄ treatment for three weeks. IHC stained with antibodies of COL1A1, F4/80, α -SMA, FOXM1, MAT α 2, and MAT2 β . H&E is shown in the top row. **b, c** show changes in ALT ($n = 6$ per group) (**b**) and AST ($n = 6$ in prevention group of Oil + DMSO, $n = 5$ in prevention group of Oil + FDI-6, $n = 3$ in prevention group of CCl₄ + DMSO and treatment group of Oil + FDI-6, $n = 4$ in prevention group of CCl₄ + FDI-6, and treatment groups of Oil + DMSO, CCl₄ + DMSO, and CCl₄ + FDI-6) (**c**) levels after FDI-6 administration in the prevention and treatment groups. Data presented as mean $\pm$ SEM, $^{**}p < 0.01$, $^{****}p < 0.0001$. **d** Hydroxyproline content was measured in the livers from prevention and treatment groups with or without FDI-6 administration. Data presented as mean $\pm$ SEM, $^{**}p < 0.01$, $^{****}p < 0.0001$ ($n = 5$ per group). **e** mRNA levels of *Foxm1*, *Mat2a*, and *Mat2b* in the livers after FDI-6 administration in the prevention and treatment groups. Data presented as

mean $\pm$ SEM ($n = 4$), $^{**}p < 0.01$, $^{****}p < 0.0001$ ($n = 4$ in prevention and treatment groups of Oil + DMSO for *Foxm1* mRNA; $n = 6$ in prevention and treatment groups of Oil + DMSO for *Mat2a* and *Mat2b* mRNA; $n = 4$ in prevention and treatment groups of Oil + FDI-6 for *Foxm1* mRNA; $n = 6$ in prevention and treatment groups of Oil + FDI-6 for *Mat2a* and *Mat2b* mRNA level; $n = 4$ in prevention group of CCl₄ + DMSO for *Foxm1* mRNA level; $n = 6$ in prevention and treatment groups of CCl₄ + DMSO for *Mat2a* and *Mat2b* mRNA and treatment group of CCl₄ + DMSO for *Foxm1* mRNA; $n = 5$ in treatment group of CCl₄ + FDI-6 for *Foxm1* mRNA level; $n = 6$ in prevention and treatment groups of CCl₄ + FDI-6 for *Mat2a* and *Mat2b* mRNA and prevention group of CCl₄ + FDI-6 for *Foxm1* mRNA. **f** Protein levels of FOXM1, MAT α 2, MAT2 β , α -SMA, F4/80, and COL1A1 from livers after prevention and treatment with FDI-6 ($n = 3$ independent experiments). Densitometry values for protein levels are summarized in Supplementary Fig. 3e, f. Statistical significance was determined by using two-tailed, unpaired Student's *t*-test. Source data are provided as a Source Data file. Abbreviations: ALT alanine transaminase, AST aspartate aminotransferase.

(Fig. 8a–d, see Supplementary Fig. 14a–d for densitometric changes). We also evaluated whether hepatocytes and HSCs can transfer EVs to KCs in vitro. Contrary to what we observed in vivo, the treatment of KCs with EVs from hepatocytes or HSCs from Flox mice after BDL showed an increase in the expression of FOXM1, MAT α 2 and MAT2 β when compared to EVs from hepatocytes from *Foxm1*^{Hep-/-} or HSCs from *Foxm1*^{HSC-/-} after BDL (Fig. 8e, f, see Supplementary Fig. 14e, f for densitometric changes). After BDL, we also found that EVs isolated from hepatocytes of *Foxm1*^{Hep-/-}, HSCs of *Foxm1*^{HSC-/-}, and KCs of *Foxm1*^{KC-/-} have lower protein expression of FOXM1, MAT α 2, and MAT2 β (Supplementary Fig. 14g) as compared to EVs from respective WT cells. Characterization of these EVs suggest they are most likely exosomes based on the size distribution (Supplementary Fig. 14h). These results suggest that FOXM1, MAT α 2 and MAT2 β are released by hepatocytes, HSCs and KCs in EVs and they can influence the expression of these proteins in other liver cell types.

Discussion


Liver fibrosis is associated with high morbidity and mortality, and liver transplantation is currently the most effective way to cure liver fibrosis²¹. Although FOXM1 is involved in multiple diseases²², such as pulmonary fibrosis, diabetes, vascular diseases, and psoriasis, earlier studies regarding FOXM1 mainly focused on its function in oncogenesis^{2,3,23–26}. In recent studies, Kurahashi et al.³ identified hepatocyte FOXM1 as a crucial driver of chronic liver inflammation as hepatocyte specific FOXM1 transgenic mice developed spontaneous liver inflammation, fibrosis, and HCC. However, the level of expression in a transgenic model is not physiologic so the role of endogenous FOXM1 in liver fibrogenesis is still not confirmed. FDI-6 could inhibit corneal inflammation, and subsequently attenuated subconjunctival fibrosis^{8,9}. However, how FOXM1 causes liver inflammation and fibrosis is uncertain and whether inhibiting FOXM1 can be effective in the treatment of existing liver fibrosis has not been investigated. We and others have shown MAT2A and MAT2B are essential for HSCs activation and liver fibrosis^{10,12–14}. In the current work, we examined if there is interplay between FOXM1 and MAT2A/MAT2B. We also investigated the contribution of cell-type-specific FOXM1 expression in liver inflammation and fibrosis.

Consistent with previous reports, the expression of FOXM1, MAT2A and MAT2B is induced in human and murine liver fibrosis. Following BDL, the cytoplasmic and nuclear content of all three proteins increased. MAT2A is best known as the gene that encodes the α 2 catalytic subunit of MATII, which catalyzes the biosynthesis of SAME in non-hepatic cells and non-parenchymal cells of the liver¹¹. We and others have shown that MAT α 2 is present in the nucleus where it can regulate gene expression via epigenetics and as a transcription factor^{27,28}. MAT2B is best known as the gene encoding for the

regulatory subunit β that regulates the activity of MATII by lowering its K_m for methionine and K_i for SAME¹⁰. MAT2A and MAT2B are often regulated in parallel, and both are overexpressed in many cancers¹⁰. MAT α 2 and MAT2 β also stabilize each other²⁹. Here we found they also regulate each other positively at the transcriptional level and form a positive regulatory loop with FOXM1 so that knocking down any of them can be effective in stopping the progression of liver fibrosis. Consistently, FDI-6 treatment, which is a specific inhibitor of FOXM1, lowered the cytoplasmic and nuclear expression of FOXM1, MAT α 2 and MAT2 β in activated HSCs, LX-2 cells, and cholangiocytes after BDL. Importantly, FDI-6 was effective in preventing as well as stopping the progression and regressing already established liver fibrosis that was induced by three weeks of CCl₄ treatment. These results suggest FDI-6 may be a potential therapy in liver fibrosis through inhibiting the FOXM1/MAT2A/2B axis.

FOXM1 activates transcription of many oncogenes, such as cell cycle-related genes, and interacts with proteins to enhance the oncogenesis via its winged helix DNA-binding domain^{3,30}. We also showed that FOXM1 activates NF- κ B and forms a complex with NF- κ B to bind to the FOX elements of the *FOXM1* and *MAT1A* promoters to activate the former but repress the latter, thereby explaining why FOXM1 and MAT1A exert reciprocal negative regulation against each other². NF- κ B subunit p65 was reported to *trans*-activate the *MAT2A* promoter^{10,14}, and we have shown that overexpression of MAT2A increased NF- κ B reporter activity²⁸, suggesting NF- κ B and MAT2A form a positive regulatory loop. In this work, we found that FOXM1, MAT2A and MAT2B exert reciprocal positive regulation on each other via FOX binding sites present in their promoters. MAT α 2 and MAT2 β are not able to bind to the FOX element alone, but they were able to in the presence of FOXM1. This is because they can directly interact with FOXM1, as demonstrated by using recombinant proteins in Co-IP experiments. Interestingly, FDI-6 not only lowered the expression of the FOXM1, MAT2A and MAT2B, it also lowered their interaction. Human cirrhosis tissues also confirmed direct correlation between *FOXM1*, *MAT2A*, and *MAT2B* mRNA levels and upregulation of all three at the mRNA level. Interestingly, high levels of all three were noted in those with HBV infection. One plausible explanation is that the X protein of HBV was shown to increase MAT2A expression at the transcriptional level³¹. This could then further increase the expression of FOXM1 and MAT2B.

Hepatocytes damage underlies multiple acute and chronic liver diseases and contribute to disease progression^{15,32}, such as inflammation and liver fibrosis. HSCs activation forms the basis of liver fibrosis. KCs also enhance hepatic fibrosis by promoting activated HSCs survival in an NF- κ B-dependent manner^{16,33}. In addition, IL-1 and TNF- α mediate the crosstalk between KCs and HSCs¹⁶. To better understand the role of FOXM1 in a cell-type specific manner, we constructed *Foxm1*^{Hep-/-}, *Foxm1*^{HSC-/-}, and *Foxm1*^{KC-/-} mice. We found that all three



cell-type-specific knockouts were able to attenuate liver injury as measured by ALT and AST to comparable degrees and lowered liver fibrosis induced by BDL. *Foxm1*^{Hep-/-} mice also had less F4/80 number and ductular proliferation, which were unchanged in *Foxm1*^{HSC-/-} mice whereas *Foxm1*^{KC-/-} mice had less F4/80 number but no change in ductular proliferation. These results seem to suggest lowering F4/80

number or ductular proliferation were not the key determinants of protection in this model.

Unexpectedly we found deletion of *Foxm1* in a cell-type-specific manner influenced the expression of FOXM1 in other cell types after BDL. Although we cannot rule out the possibility that there was leakiness in the Cre-lox system, our results suggest another explanation,

Fig. 3 | FOXM1, MAT α 2 and MAT2 β regulate each other positively at the transcriptional level. **MAT2A** (a), **MAT2B** (b) and **FOXM1** (c) promoter activities in LX-2 cells and primary cholangiocytes $\pm$ FDI-6 or siRNA treatment as described in Methods. Effects of mutating FOX elements in LX-2 cells are shown in (d) **MAT2A**, (e) **MAT2B**, and (f) **FOXM1**. Cells transfected with WT and mutant constructs were treated with siRNA against MAT2A, MAT2B, and FOXM1 and reporter activities were measured. Data presented as mean $\pm$ SEM ($n = 3$ per group). For a, *Mat2a* promoter activities of D-271/+60, D-671/+60 and D-1329/+60 in LX2 cell, SC + DMSO vs. SC + FDI-6, $p = 0.0002$, $p = 0.0052$ and $p = 0.0948$, respectively; SC + DMSO vs. SC + FOXM1 si, $p = 0.0001$, $p = 0.0022$ and $p = 0.0003$, respectively; *Mat2a* promoter activities of D-271/+60 in cholangiocytes, SC + DMSO vs. SC + FDI-6 or SC + Foxm1si, $p = 0.0286$ and 0.0149 , respectively. For b, *Mat2b* promoter activities of D-25/+3, D-713/+3, D-990/+3 and D-1319/+3 in LX2 cell, SC + DMSO vs. SC + FDI-6, $p = 0.0051$, $p = 0.0316$, $p = 0.016$ and $p = 0.0034$, respectively; SC + DMSO vs. SC + FOXM1 si, $p = 0.0106$, $p = 0.0233$, $p = 0.0019$ and $p = 0.0049$ respectively; *Mat2b* promoter activities of D-250/+3 in cholangiocytes, SC + DMSO vs. SC + FDI-6 or SC + Foxm1 si, $p = 0.0002$ and 0.023 , respectively. For c, *Foxm1* promoter activities of D-312/+107 and D-1333/+107 in LX2 cell, SC + DMSO vs. SC + FDI-6, $p = 0.5799$ and $p = 0.0020$, respectively; SC + DMSO vs. SC + FOXM1 si, $p = 0.7684$ and $p = 0.0047$ respectively; *Foxm1* promoter activities of D-1333/+107 in cholangiocytes, SC + DMSO vs. SC + FDI-6 or SC + Foxm1 si, $p = 0.0163$ and 0.0131 , respectively. For d, *Mat2A* promoter activities (−270/+60) of WT and MU, SC vs. SC, $p = 0.015$ and $p = 0.28$ respectively; FOXM1si vs. SC, $p = 0.0032$ and $p = 0.042$ respectively; MAT2Asi vs. SC, $p = 0.0033$ and $p = 0.066$ respectively. For e, *Mat2B* promoter activities (−250/+3) of WT and MU, SC vs. SC, $p = 0.0017$ and $p = 0.11$ respectively; FOXM1si vs. SC, $p = 0.0018$ and $p = 0.022$ respectively; MAT2Asi vs. SC, $p = 0.0015$ and $p = 0.026$ respectively. For f, *FOXM1* promoter activities (−1333/+107) of WT and MU, SC vs. SC, $p = 0.000017$ and $p = 0.0078$ respectively; FOXM1si

vs. SC, $p = 0.000014$ and $p = 0.0063$ respectively; MAT2Asi vs. SC, $p = 0.00020$ and $p = 0.019$ respectively. **g** ChIP assay was performed by spanning two FOX regions of the *FOXM1* promoter in LX-2 cells using FOXM1, MAT α 2 and MAT2 β antibodies after treatments that varied the expression of FOXM1, MAT2A or MAT2B in the top three rows. Seq-ChIP with anti-MAT α 2 and MAT2 β antibodies after FOXM1 ChIP was performed as described in Methods. Representative results from three experiments are shown. **h** qPCR analysis of the ChIP assay from (g). For **h**, ChIP and Seq-ChIP percentage of input DNA, FOXM1 si vs. SC, MAT2A si vs. SC, MAT2B si vs. SC, FOXM1 OV vs. EV, MAT2A OV vs. EV, and MAT2B OV vs. EV, for FOXM1 ChIP, $p = 0.00089$, $p = 0.011$, $p = 0.0045$, $p = 0.0000053$, $p = 0.00024$, and $p = 0.000039$; for MAT2A seq-ChIP $p = 0.0015$, $p = 0.0023$, $p = 0.0037$, $p = 0.000037$, $p = 0.00076$, and $p = 0.00032$; for MAT2B seq-ChIP $p = 0.0036$, $p = 0.018$, $p = 0.0092$, $p = 0.0036$, $p = 0.0000098$, $p = 0.0013$ respectively. Data presented as mean $\pm$ SEM, * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ vs. SC or EV ($n = 3$ independent experiments). **i** EMSA was done using labeled probes containing two FOX binding motifs of the *FOXM1* promoter as shown in (f) and 100 ug of nuclear protein from LX-2 cells after treatments that varied FOXM1/MAT2A/MAT2B ($n = 3$ independent experiments). **j** Super shifts were done using 100 ng of recombinant proteins of FOXM1, MAT α 2, MAT2 β alone or combined, and antibodies to FOXM1, MAT α 2 and MAT2 β . Probe and IgG only served as negative controls. Results represent three independent experiments. **k** In vitro pull-down shows direct interaction between MAT α 2, MAT2 β and FOXM1 using recombinant MAT α 2, MAT2 β and FOXM1 proteins ($n = 3$ independent experiments). **l** MAT α 2, MAT2 β and FOXM1 interaction in Flox control (WT), *Foxm1*^{flp}−/−, with or without BDL was detected by Co-IP and western blotting ($n = 3$ independent experiments). Statistical significance was determined by using two-tailed, unpaired Student's *t*-test. Source data are provided as a Source Data file. Abbreviations: AB antibody, EV empty vector, IP immunoprecipitation, OV over-expression, si siRNA, WT wild type, MU mutants.

namely exchange/transfer of FOXM1, MAT α 2 and MAT2 β amongst different cell types via EVs. Consistently, HSCs and hepatocytes from respective knockouts had lower levels of FOXM1, MAT α 2 and MAT2 β when treated with EVs from knockouts as compared to WTs after BDL. Indeed, EVs and their cargo transfer various cellular materials and signals (RNA, DNA, proteins, and lipids) between neighboring or distant cells, playing vital roles in the development of metabolic diseases and cancer^{34–37}. Transfer of EVs enriched in FOXM1, MAT α 2 and MAT2 β between hepatocytes, HSCs, and KCs can maintain sustained activation of HSCs and KCs. Other studies have shown hepatocytes, HSCs, and KCs interaction via EVs^{38,39}. We cannot exclude the possibility that other components of the EVs are also involved to modulate the changes in the expression of these three proteins.

Also, it is interesting that in vivo after BDL, hepatocyte-specific and HSC-specific *Foxm1* deletion attenuated *Foxm1/Mat2a/Mat2b* induction in each other but they had no influence on their expression in KCs. This is in contrast to in vitro treatment of KCs with EVs from hepatocytes or HSCs after BDL that clearly showed an increase in the expression of FOXM1, MAT α 2 and MAT2 β as compared to EVs from KO hepatocytes or HSCs. One consideration is the spatial relationship of these cells. For instance, hepatocytes and HSCs are in close contact with each other but KCs are in the sinusoids, separated from the other two cell types by sinusoidal endothelial cells. However, KC-specific *Foxm1* KO mice had lower expression of *Foxm1/Mat2a/Mat2b* in hepatocytes and HSCs after BDL. One possibility is that *Foxm1* deleted KCs are releasing less proinflammatory cytokines which are known to induce *Foxm1* and *Mat2a*^{2,10}. Another observation is that In vivo the cholangiocytes do not appear to be influenced by the EVs released by the other three cell types. At present we are not sure of the underlying mechanisms, but one speculation is how the different cells receive their blood supply. Bile duct epithelial cells receive their blood supply from the hepatic artery⁴⁰. It is possible that hepatocytes release EVs mainly into sinusoidal blood under our experimental conditions.

Since FOXM1, MAT2A and MAT2B are positively regulating each other and their encoded proteins all physically interact, we resorted to testing how essential they are in fibrogenesis and inflammation using overexpression and knockdown. TGF- β 1 pathway plays an essential

role in the pathogenesis of liver fibrosis and it is known to activate NF- κ B subunit p65, which contributes to TGF- β 1-induced HSCs activation^{10,14}. Macrophage-derived TGF- β 1 is the most potent known fibrogenic agonist¹⁶. LPS increases liver injury and inflammation via the release of inflammatory cytokines⁴¹, such as TNF- α and IL-6. We found FOXM1, MAT α 2 and MAT2 β , α -SMA and COL1A1 were all increased at three hours and since TGF- β 1 activates NF- κ B, which activates both FOXM1² and MAT2A¹⁴, they may be induced simultaneously. However, after BDL, the induction in FOXM1 occurred slightly earlier, suggesting FOXM1 is induced first in vivo. Knocking down any of the three reduced fibrogenic markers and although FOXM1 overexpression can augment TGF- β 1 signaling, this requires participation of MAT2A and MAT2B. A similar scenario also occurs with LPS-induced proinflammatory cytokines in macrophages, where knocking down any of the three attenuated/eliminated LPS' effect and MAT2A and MAT2B are required for FOXM1 to exert its full pro-inflammatory effect. These results support the notion that the FOXM1-MAT2A-MAT2B axis is essential for liver fibrosis and inflammation.

Methods


The study protocol was approved by the Institutional Animal Care and Use Committee of CSMC (No. 8850).

Materials and reagents

See Supplementary Table 2 for a list of the reagents and sources.

Human samples

Microarrays for 16 healthy human liver (HHL), 24 cases of hepatitis and 28 cases of cirrhosis tissues were from US biolab Inc. (Cat# DLV20812A, Rockville, MD, <https://usbiolab.com/index.php/tissue-array/product/liver/DLV20812a>). Four cases of PSC and three cases of PBC human liver specimens obtained from liver biopsy from 2014–2019, and five healthy liver tissues obtained from surgical resection for patients suffering from intrahepatic ductal stones from 2018–2019 were obtained from the department of Pathology at the Xiangya Hospital Central South University, Changsha, Hunan province, China. The samples were embedded in paraffin and stored in the institutional



biobank. PSC, PBC and healthy tissues were evaluated histologically to confirm presence or absence of cancer.

For mRNA assays of *FOXMI*, *MAT2A* and *MAT2B* in healthy human livers (NHL), ten case of healthy control samples were obtained from surgical resection of hepatic hemangioma. None of the healthy control individuals underwent preoperative chemotherapy, and liver histology

demonstrated absence of both cirrhosis and malignancy. Liver tissues were immediately frozen in liquid nitrogen. Thirty-one patients with cirrhosis were diagnosed at Xiangya Hospital Central South University from 2016–2021. There was no bias in the selection of patients. The sex of the participants was self-reported, and neither sex nor gender was considered during participant selection. Liver biopsies were evaluated

Fig. 4 | Response of hepatocyte specific *Foxm1* knockout (*Foxm1*^{Hep-/-}) mice to BDL. **a** H&E, Sirius red, CK19, α -SMA, and F4/80 staining in Flox control and *Foxm1*^{Hep-/-} mice after BDL as compared to sham surgery. Liver fibrosis was measured by Sirius red staining ($n = 7$ per group) (**b**) and hydroxyproline assay ($n = 5$ per group) (**c**), liver injury by ALT ($n = 6$ per group) (**d**) and AST ($n = 6$ per group) (**e**) levels, macrophage number by F4/80 ($n = 6$ per group) (**f**), and ductular proliferation by CK19 ($n = 4$ per group) and myofibroblast differentiation by α -SMA staining ($n = 3$ per group) (**g**). For **b**, Sirius red area/total area for Flox BDL vs. Sham and Hep-/- BDL vs. Flox BDL, $p = 0.00000000011$ and $p = 0.0000015$, respectively. For **c**, hydroxyproline (ug/g, liver) for Flox BDL vs. Sham and Hep-/- BDL vs. Flox BDL, $p = 0.000058$ and $p = 0.0034$, respectively. For **d**, ALT level (ug/L) for Flox BDL vs. Sham and Hep-/- BDL vs. Flox BDL, $p = 0.00000000014$ and $p = 0.0000000097$, respectively. For **e**, AST level (ug/L) for Flox BDL vs. Sham and Hep-/- BDL vs. Flox BDL, $p = 0.000000000001$ and $p = 0.00000025$, respectively. For **f**, F4/80 positive number for Flox BDL vs. Sham and Hep-/- BDL vs. Flox BDL, $p = 0.0000000020$ and $p = 0.00080$, respectively. For **g**, CK19/total area for Flox BDL vs. Sham and Hep-/- BDL vs. Flox BDL, $p = 0.00000078$ and $p = 0.00026$, respectively. Data are shown as mean $\pm$ SEM, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$. **h** Protein expression of FOXM1, MAT2 α , and MAT2 β in hepatocytes, cholangiocytes, HSCs, and KCs isolated from Flox control and *Foxm1*^{Hep-/-} mice $\pm$ BDL. Densitometry values for protein levels are summarized in Supplementary Fig. 11a–d. mRNA levels of *Foxm1*, *Mat2a*, and *Mat2b* in hepatocytes ($n = 6$ animals in Flox + Sham, *Foxm1*^{Hep-/-} + Sham, Flox + BDL groups and *Foxm1*^{Hep-/-} + BDL group for *foxm1* and *mat2b* mRNA; $n = 4$ in Flox + Sham, *Foxm1*^{Hep-/-} + Sham, Flox + BDL groups and $n = 6$ in *foxm1*^{Hep-/-} + BDL group for *mat2a* mRNA) (**i**), cholangiocytes ($n = 4$ animals in Flox + Sham, *foxm1*^{Hep-/-} + Sham, Flox + BDL groups and *foxm1*^{Hep-/-} + BDL groups for *foxm1* mRNA; $n = 5$ in Flox + Sham and

foxm1^{Hep-/-} + Sham groups and $n = 4$ in Flox + BDL and *Foxm1*^{Hep-/-} + BDL groups for *mat2a* mRNA; $n = 6$ in Flox + Sham, *Foxm1*^{Hep-/-} + Sham, Flox + BDL groups and *foxm1*^{Hep-/-} + BDL group for *mat2b* mRNA) (**j**), HSCs ($n = 6$ animals) (**k**), and KCs ($n = 4$ animals in Flox + Sham, Flox + BDL groups, *foxm1*^{Hep-/-} + BDL groups and $n = 5$ in *foxm1*^{Hep-/-} + Sham for *foxm1* mRNA; $n = 5$ in Flox + Sham and *foxm1*^{Hep-/-} + Sham groups, Flox + BDL and *Foxm1*^{Hep-/-} + BDL groups for *mat2a* mRNA; $n = 5$ in Flox + Sham, Flox + BDL and *Foxm1*^{Hep-/-} + BDL groups and $n = 6$ in *foxm1*^{Hep-/-} + Sham group for *mat2b* mRNA). **l** isolated from Flox control, *Foxm1*^{Hep-/-} mice $\pm$ BDL. Data are shown as mean fold of Flox control $\pm$ SEM, * $p < 0.05$, ** $p < 0.001$, **** $p < 0.0001$. p values obtained via two-tailed unpaired Student's t tests. For **i**, mRNA levels in hepatocytes, fold of Flox con of FOXM1, MAT2A, and MAT2B of Flox BDL vs. Sham $p = 0.0000045$, $p = 0.000030$, and $p = 0.000028$ respectively; of Hep-/- BDL vs. Flox BDL $p = 0.000000099$, $p = 0.00024$, $p = 0.000099$ respectively. For **j**, mRNA levels in cholangiocytes, fold of Flox con of FOXM1, MAT2A, and MAT2B of Flox BDL vs. Sham $p = 0.00023$, $p = 0.00000026$, and $p = 0.000000011$, respectively; of Hep-/- BDL vs. Flox BDL $p = 0.0000041$, $p = 0.013$, and $p = 0.0000031$, respectively. For **k**, mRNA levels in HSCs, fold of Flox con of FOXM1, MAT2A, and MAT2B of Flox BDL vs. Sham, $p = 0.000000000005$, $p = 0.000000067$, and $p = 0.0000000000$ respectively; of Hep-/- BDL vs. Flox BDL $p = 0.00000000050$, $p = 0.00025$, and $p = 0.0000000011$ respectively. For **l**, mRNA levels in KCs, fold of Flox con of FOXM1, MAT2A, and MAT2B of Flox BDL vs. Sham, $p = 0.000041$, $p = 0.000010$, and $p = 0.00000035$ respectively; of Hep-/- BDL vs. Flox BDL $p = 0.84$, $p = 0.16$, and $p = 0.62$ respectively. Statistical significance was determined by using two-tailed unpaired Student's t -test. Source data are provided as a Source Data file. Abbreviations: ALT alanine transaminase, AST aspartate aminotransferase, BDL bile duct ligation, Cho cholangiocytes, HSCs hepatic stellate cells, Hep hepatocytes, KCs Kupffer cells.

blindly by two expert hepatopathologists. Hepatitis B surface antigen (HBsAg) was measured with a commercial enzyme immunoassay (Shanghai Kehua Bio-engineering Co. Ltd Shanghai). Total RNA of NHL and cirrhosis was extracted from stored frozen liver specimens using QIAzol (Qiagen) reagent according to the manufacturer's recommendations, and RNA quality and integrity were assessed using the RNA 6000 Nano assay on the Agilent 2100 Bioanalyzer. mRNA levels of *FOXM1*, *MAT2A* and *MAT2B* were measured by TaqMan. The research was conducted under both the Declarations of Helsinki and Istanbul, and the study protocol was approved by the IRB and the Medical Ethical Committee of Xiangya Hospital Central South University. All human materials were obtained with patients' informed written consent.

Mice

Four-month-old male C57BL/6 littermates were used for this study. Male mice were used because they are more susceptible to liver fibrosis. Mice were housed with ad libitum access to food (diet: CAT#5053, Picolab, San Francisco, CA) and water and kept on a 12 h (8 a.m. to 8 p.m.) light-dark cycle in a temperature (72–77°F) and humidity (42%) controlled room at the animal facility of the Cedars-Sinai Medical Center (CSMC). Care of animals was within institutional animal care committee guidelines. Mice were euthanized using ketamine (100 mg/kg, intraperitoneally).

Generation of cell-type-specific *Foxm1* knockout mice

Generation of *Foxm1*^{Hep-/-} mice.

- Foxm1*^{fl/fl} mice (Jackson Laboratory) were cross bred with *Alb-Cre* mice (Jackson Laboratory) transgenic mice. *Foxm1*^{fl/fl}Cre-negative littermates served as WT controls. Cell type-specific knockouts were confirmed by isolation of liver cells and messenger RNA (mRNA) expression. Twelve-week-old mice were used for the BDL experiments. All animal experiments were approved by the Institutional Review Board of the Cedars-Sinai Medical Center. Sequences of primers of forward 5'-TGGCTTCCCAGCAGTA-CAAATC-3' and reverse 5'-TGCTTACAAAGACACACTTGGACG'. The PCR reaction consisted of an initial denaturation at 94 °C for 3 min followed by 35 cycles at 95 °C for 30 s, annealing at 60 °C for

one minute and extension at 72 °C for one minute using the 2XTaq red master (Apex, El Cajon, CA, Cat #: 42-138). PCR analysis of *Foxm1*^{Hep-/-}, *Foxm1*^{Hep+/+} and *Foxm1*^{Hep+/+} depicted in Supplementary Fig. 10a.

Generation of *Foxm1*^{HSC-/-} mice.

- Foxm1*^{fl/fl} mice were crossed with *Lrat-Cre* transgenic mice (kindly provided by Dr. Robert Schwabe, Columbia University). Mice were back-crossed at least 10 generations onto the C57BL/6 background. *Foxm1*^{fl/fl}Cre-negative littermates served as WT controls. Sequences of primers of forward 5'-CCTTCTTTGACCCCTG-CAG-3' and reverse 5'-GACCGGCAACGGACAGAAG'. The PCR reaction is same as *Foxm1*^{Hep-/-}. PCR analysis of *Foxm1*^{HSC-/-}, *Foxm1*^{HSC+/+} and *Foxm1*^{HSC+/+} depicted Supplementary Fig. 10b.


Generation of *Foxm1*^{KC-/-} mice.

- Foxm1*^{fl/fl} mice were cross bred with *Clec4f-Cre* (Jackson Laboratory) transgenic mice. *Foxm1*^{fl/fl}Cre-negative littermates served as WT controls. Sequences of primers for mutant reverse 5'-ACACCGGCTTATTCCAAG-3', wild type reverse 5'-GAAAGACCCAA GGAAGGAG-3' and common 5'-CAAGAAGTCCACAGGGTGGT-3'. The PCR reaction is same as *Foxm1*^{Hep-/-}. PCR analysis of *Foxm1*^{KC-/-}, *Foxm1*^{KC+/+} and *Foxm1*^{KC+/+} depicted in Supplementary Fig. 10c.

Genomic DNA from mouse ears was isolated and amplified by PCR for analysis of *Foxm1*^{Hep-/-}, *Foxm1*^{HSC-/-}, and *Foxm1*^{KC-/-} genotypes.

Carbon tetrachloride treatment and BDL

Mice were housed in a room maintained at a temperature of 22 °C and relative humidity of 50 $\pm$ 10% with alternating 12 h of light and darkness. Mice were acclimatized for one week prior to use and had free access to food and water during the entire experiment. In the CCl₄ groups, mice were intraperitoneally (i.p) injected with 0.3% CCl₄ (10 mL/kg, dissolved in corn oil). 64 mice at 8-weeks of age were randomly assigned to two groups: a prevention group and a treatment group. Prevention and treatment groups were divided into subgroups of Oil + DMSO, Oil + FDI-6, Oil + CCl₄ and CCl₄ + FDI-6. CCl₄ was given via i.p. injection three times/week for 3 weeks in prevention group and



5 weeks in the treatment group. FDI-6 was dissolved in 10% DMSO and diluted in 90% corn oil (final concentration: 2.5 mg/mL). FDI-6 treatment was given at 25 mg/kg/d via direct i.p. injection three times/week started at the same time as CCl₄ in the prevention group versus after 3 weeks of CCl₄ in the treatment group and continued with CCl₄ for 2 weeks.

For BDL surgery, 32 mice at 3-months of age from *Foxm1*^{Hep-/-}, *Foxm1*^{HSC-/-}, *Foxm1*^{KC-/-} or flox controls were fed chow ad libitum and housed at constant temperature (22 °C) with alternating 12 h of light and darkness. Following i.p. injection of ketamine (80 mg/kg) and xylazine (10 mg/kg), the common bile duct was exposed through a midline abdominal incision, ligated in two places with a silk thread and

Fig. 5 | Response of hepatic stellate cell (HSC)-specific *Foxm1* knockout (*Foxm1*^{HSC-/-}) mice to BDL. **a** H&E, Sirius red, CK19, α -SMA, and F4/80 staining in Flox control and *Foxm1*^{HSC-/-} mice after BDL as compared to sham surgery. Liver fibrosis was measured by Sirius red staining ($n = 8$ animals per group) (**b**) and hydroxyproline assay ($n = 6$ animals per group) (**c**), liver injury by ALT ($n = 6$ animals in Flox + Sham, Flox + BDL and *Foxm1*^{HSC-/-} + BDL groups and $n = 5$ in *Foxm1*^{HSC-/-} + Sham) (**d**) and AST ($n = 7$ in Flox + Sham, Flox + BDL groups and $n = 6$ in Flox + BDL group and $n = 5$ in *Foxm1*^{HSC-/-} + BDL) (**e**) levels, macrophage number by F4/80 ($n = 4$ animals per group) (**f**), and ductular proliferation by CK19 staining ($n = 6$ animals per group) and myofibroblast differentiation by α -SMA staining ($n = 3$ animals per group) (**g**). For **b**, Sirius red area/total area of Flox BDL vs. Sham and HSC-/- BDL vs. Flox BDL, $p = 0.0000000015$ and $p = 0.0000060$ respectively. For **c**, hydroxyproline (ug/g, liver) for Flox BDL vs. Sham and HSC-/- BDL vs. Flox BDL, $p = 0.00000012$ and $p = 0.000094$ respectively. For **d**, ALT level (ug/L) for Flox BDL vs. Sham and HSC-/- BDL vs. Flox BDL, $p = 0.000000041$ and $p = 0.0000013$ respectively. For **e**, AST level (ug/L) for Flox BDL vs. Sham and HSC-/- BDL vs. Flox BDL, $p = 0.0000000066$ and $p = 0.00044$ respectively. For **f**, F4/80 positive number for Flox BDL vs. Sham and HSC-/- BDL vs. Flox BDL, $p = 0.0000000071$ and $p = 0.0073$ respectively. For **g**, Flox BDL vs. Sham and HSC-/- BDL vs. Flox BDL for CK19/total area, $p = 0.000000000075$ and $p = 0.080$ respectively; for α -SMA area/total area, $p = 0.000026$ and $p = 0.00011$ respectively. Data are shown as mean $\pm$ SEM, *** $p < 0.001$, **** $p < 0.0001$. **h** Protein expression of FOXM1, MAT α 2, and MAT2 β in hepatocytes, cholangiocytes, HSCs, and KCs isolated from Flox control and *Foxm1*^{HSC-/-} mice $\pm$ BDL. Densitometry values for

protein levels are summarized in Supplementary Fig. 11e, f. mRNA levels of *Foxm1*, *Mat2a*, and *Mat2b* in hepatocytes ($n = 6$ per group) (**i**), cholangiocytes ($n = 6$ per group) (**j**), HSCs ($n = 6$ per group) (**k**), and KCs ($n = 6$ per group) (**l**) isolated from Flox control and *Foxm1*^{HSC-/-} mice $\pm$ BDL. Data are shown as mean fold of Flox control $\pm$ SEM, **** $p < 0.0001$, and ns not significant. p values obtained via two-tailed unpaired Student's t tests. For **i**, mRNA levels in Hepatocytes, fold of Flox con of FOXM1, MAT2A, MAT2B for Flox BDL vs. Sham, $p = 0.0000000000004$, $p = 0.0000000000001$ and $p = 0.0000000000072$ respectively; for HSC-/- BDL vs. Flox BDL, $p = 0.000000000022$, $p = 0.000000000020$, and $p = 0.0000000054$ respectively. For **j**, mRNA levels in Cholangiocytes, fold of Flox con of FOXM1, MAT2A, and MAT2B for Flox BDL vs. Sham $p = 0.0000000000000$, $p = 0.0000000028$, and $p = 0.0000000085$ respectively; for HSC-/- BDL vs. Flox BDL, $p = 0.17$, $p = 0.42$, and $p = 0.46$ respectively. For **k**, mRNA levels in HSCs, fold of Flox con of FOXM1, MAT2A, and MAT2B for Flox BDL vs. Sham $p = 0.0000052$, $p = 0.0000000000$, and $p = 0.0000000000$ respectively; for HSC-/- BDL vs. Flox BDL, $p = 0.00000056$, $p = 0.00018$, and $p = 0.00000000002$ respectively. For **l**, mRNA levels in KCs, fold of Flox con of FOXM1, MAT2A, and MAT2B for Flox BDL vs. Sham $p = 0.000000000091$, $p = 0.00036$, and $p = 0.00000010$ respectively; for HSC-/- BDL vs. Flox BDL, $p = 0.086$, $p = 0.61$, and $p = 0.15$ respectively. Statistical significance was determined by using two-tailed unpaired Student's t -test. Source data are provided as a Source Data file. Abbreviations: ALT alanine transaminase, AST aspartate aminotransferase, BDL bile duct ligation, Cho cholangiocytes, HSCs hepatic stellate cells; Hep hepatocytes, KCs Kupffer cells.

sectioned between the ligatures. Sham operated mice had anesthesia and laparotomy only. The serum and partial liver tissues were used for assays of ALT, AST, hydroxyproline and IHC. The hepatic cells were isolated for studies described below and used for western blots and mRNA determinations.

For time-course of FOXM1, MAT2 α and MAT2 β during BDL, C57BL/6 mice (9–10 weeks) were anesthetized with isoflurane and subjected to midline laparotomy (~1 cm) to expose the common bile duct (CBD). Two knots were made on the CBD using a 5–0 silk suture and then, the CBD was cut between the two knots. The peritoneum was re-aligned, and the underneath muscle layers and skin were closed individually using a 5–0 silk suture. Mice. Briefly, mice were fed ad libitum with diet for 5 days and then divided into six groups of the day 0, 1, 2, 3, 7 and 14 ($n = 6$ per group, 36 total). Sham operation was on day 0. Sera and liver tissues were collected for various assays and cell isolation. Eight Flox male mice at three months of age were used for cholangiocyte isolation and promoter assays.

All procedure protocols, use, and the care of the animals were reviewed and approved by the Institutional Animal Care and Use Committee at Cedars-Sinai Medical Center and all experiments involving research animals were conducted in accordance with all relevant ethical regulations. All mice were housed under 12-h light/12-h dark cycle at an average temperature of 74 °F and 40% humidity.

Isolation of different liver cell types

Foxm1^{Hep-/-}, *Foxm1*^{HSC-/-}, *Foxm1*^{KC-/-}, and their corresponding Flox are subjected to BDL for seven days. Isolations of primary HSCs from three-months old male knockout and wild-type animals were performed by pronase-collagenase perfusion followed by density gradient centrifugation. Briefly, after in situ perfusion of the liver with 1 mg/ml pronase (CAT#: 1145963001, Roche, Indianapolis, IN), followed by 0.35 mg/mL collagenase (CAT#: C9891-1G, Sigma), dispersed cell suspensions were layered on a discontinuous density gradient Optiprep solution (CAT#: 07820, Serumwerk, Bernburg) and washed with 1XHBSS (CAT#: 21-021-CV, CORNING). HSCs were collected from the gradient interface, and cell viability was verified by phase-contrast microscopy as well as trypan blue staining. The viability of all cell cultures used for the studies was >95%. For EVs isolation, the cells were plated at a density of 4,000,000/10 cm dish. The cells were kept in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal


bovine serum (FBS) and antibiotics in a humidified atmosphere with 5% CO₂ and 21% O₂ at 37 °C for 24 h and then changed to serum free DMEM media for 24 h. To isolate Kupffer cells, animals were performed by collagenase perfusion followed by low spin at 50 g for 5 min. The supernatants were centrifuged at 800 g for 10 min. The cell pellet was followed by density gradient centrifugation at a speed of 16,000 for 15 min. The cell fraction at middle layer was incubated with anti-F4/80 microbeads (Miltenyl Biotec, Auburn, CA) antibody for 15 min in the dark in the refrigerator (2–8 °C). The cells were washed with 1–2 ml of buffer (a solution containing phosphate-buffered saline (PBS), pH 7.2, 0.5% bovine serum albumin (BSA) and 2 mM EDTA) and spun at 300 g for 10 min and aspirated supernatant completely. For EVs isolation, the cells were plated at a density of 5,000,000/10 cm dish. To isolate hepatocytes, animals were performed by collagenase perfusion followed by low spin at 50 g for 5 min. The cell pellet was washed by Hanks' balanced salt solution (HBSS) twice. The cells were plated at a density of 3,000,000/10 cm dish. Cell culture condition for KCs and hepatocytes was the same as HSCs. Cell pellets were immediately stored at -80 °C for RNA or protein measurements.

Cell lines

LX-2 cells were kindly provided by Dr. Ekihiro Seki and the mouse macrophage cell line RAW 264.7 was purchased from American Type Cell Collection (ATCC, Manassas, VA). Both cell lines were cultured in DMEM containing 10% fetal bovine serum (FBS) and antibiotics (2 mM glutamine, 50 mM penicillin, and 50 mg/ml streptomycin sulfate).

Measurements of liver injury and fibrosis

Liver samples from CCl₄ with or without FDI-6 treatments with three kinds of *Foxm1* cell specific knockout or Flox mice were homogenized in 6 N HCl, hydrolyzed overnight at 100 °C, and centrifuged at 10,000 $\times$ g for 3 min. Supernatants were transferred to a 96-well plate and analyzed following the Hydroxyproline assay kit protocol (MAR008-1KT, Sigma). Hydroxyproline content was measured using a CLARIO Star machine (absorbance at 560 nm) and normalized to liver weight. The ALT and AST levels in serum were determined using ALT kit (CAT# TR71121, ThermoFisher) and AST kit (CAT# TR70121, ThermoFisher), respectively. The collagen proportional area (CPA) was defined as the percentage of the area positive for Sirius red staining. Sirius Red area/total area was quantified according to the value of CPA⁴².



Real-time quantitative PCR (qPCR)

Total RNA was extracted using TRIzol reagent (ThermoFisher) or QuickRNA miniPrep kit (Zymo Research, Irvine, CA) from liver tissues, hepatic cells of *Foxm1*^{Hep-/-}, *Foxm1*^{HSC-/-}, and *Foxm1*^{KC-/-}, or LX-2 (human activated HSCs) and RAW 264.7 (murine macrophages) cells. Human and mouse probes for *MAT2A*, *MAT2B* and *FOXMI*, and the PCR

Supermix were purchased from ThermoFisher. Hypoxanthine phosphoribosyltransferase 1 (HPRT1) was included as a housekeeping gene. The thermal profile comprised of initial denaturation at 95 °C for 3 min followed by 40 cycles at 95 °C for 3 s and at 60 °C for 30 s. The cycle threshold (Ct value) of the target gene was normalized to that of the HPRT1 gene to obtain the delta Ct (DCt). Relative genes expression was

Fig. 6 | Response of Kupffer cell (KC)-specific Foxm1 knockout (*Foxm1^{KC-/-}*) mice to BDL. **a** H&E, Sirius red, CK19, α -SMA, and F4/80 staining in Flox control and *Foxm1^{KC-/-}* mice after BDL as compared to sham surgery. Liver fibrosis was measured by Sirius red staining ($n = 8$ animals per group), **b** and hydroxyproline assay ($n = 5$ animals in Flox + Sham group and $n = 6$ in *Foxm1^{KC-/-}* + Sham, Flox + BDL and *Foxm1^{KC-/-}* + BDL groups) (**c**), liver injury by ALT ($n = 6$ animals per group) (**d**) and AST ($n = 6$ animals per group) (**e**) levels, macrophage number by F4/80 ($n = 6$ animals per group) (**f**), and ductular proliferation by CK19 ($n = 4$ animals per group) and myofibroblast differentiation by α -SMA staining ($n = 3$ animals per group) (**g**). For **b**, Sirius red area/total area of Flox BDL vs. Sham and KC-/- BDL vs. Flox BDL, $p = 0.00000000049$ and $p = 0.00014$ respectively. For **c**, hydroxyproline (ug/g, liver) for Flox BDL vs. Sham and KC-/- BDL vs. Flox BDL, $p = 0.00030$ and $p = 0.012$ respectively. For **d**, ALT level (ug/L) for Flox BDL vs. Sham and KC-/- BDL vs. Flox BDL, $p = 0.000000000000$ and $p = 0.000000000081$ respectively. For **e**, AST level (ug/L) for Flox BDL vs. Sham and KC-/- BDL vs. Flox BDL, $p = 0.0000000000001$ and $p = 0.00000025$ respectively. For **f**, F4/80 positive number for Flox BDL vs. Sham and KC-/- BDL vs. Flox BDL, $p = 0.0000000067$ and $p = 0.0000094$ respectively. For **g**, Flox BDL vs. Sham and KC-/- BDL vs. Flox BDL for CK19/total area, $p = 0.00000010$ and $p = 0.039$ respectively; for α -SMA area/total area, $p = 0.000026$ and $p = 0.00033$ respectively. Data are shown as mean $\pm$ SEM, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$. **h** Protein levels of FOXM1, MAT α 2, and MAT2 β in hepatocytes, cholangiocytes, HSCs, and KCs isolated from Flox and *Foxm1^{KC-/-}* mice $\pm$ BDL. Densitometry values for protein levels are

summarized in Supplementary Fig. 12a–d. mRNA levels of *Foxm1*, *Mat2a*, and *Mat2b* in hepatocytes ($n = 6$ per group) (**i**), cholangiocytes ($n = 6$ per group) (**j**), HSCs ($n = 6$ per group) (**k**), and KCs ($n = 6$ per group) (**l**) isolated from Flox control and *Foxm1^{KC-/-}* mice $\pm$ BDL. Data are shown as mean fold of Flox control $\pm$ SEM, *** $p < 0.001$, **** $p < 0.0001$, ns not significant. For **i**, mRNA levels in hepatocytes, fold of Flox con of FOXM1, MAT2A, MAT2B for Flox BDL vs. Sham, $p = 0.000000012$, $p = 0.0000019$ and $p = 0.50$ respectively; for KC-/- BDL vs Flox BDL, $p = 0.00000086$, $p = 0.00060$, and $p = 0.000000036$ respectively. For **j**, mRNA levels in cholangiocytes, fold of Flox con of FOXM1, MAT2A, and MAT2B for Flox BDL vs. Sham $p = 0.000000000001$, $p = 0.000000000005$, and $p = 0.00000000046$ respectively; for KC-/- BDL vs Flox BDL, $p = 0.071$, $p = 0.064$, and $p = 0.061$ respectively. For **k**, mRNA levels in HSCs, fold of Flox con of FOXM1, MAT2A, and MAT2B for Flox BDL vs. Sham $p = 0.0000000086$, $p = 0.0000000002$, and $p = 0.000000000$ respectively; for KC-/- BDL vs Flox BDL, $p = 0.0000032$, $p = 0.0000095$, and $p = 0.0000078$ respectively. For **l**, mRNA levels in KCs, fold of Flox con of FOXM1, MAT2A, and MAT2B for Flox BDL vs. Sham $p = 0.000000040$, $p = 0.000000033$, and $p = 0.00000075$ respectively; for KC-/- BDL vs Flox BDL, $p = 0.0000000071$, $p = 0.00000097$, and $p = 0.0000059$, respectively. Statistical significance was determined by using two-tailed unpaired Student's *t*-test. Source data are provided as a Source Data file. Abbreviations: ALT alanine transaminase, AST aspartate aminotransferase, BDL bile duct ligation, Cho cholangiocytes, HSCs hepatic stellate cells, Hep hepatocytes, KCs Kupffer cells.

calculated with $2^{-\Delta\Delta CT}$ method and normalized to HPRT1 expression ($\Delta\Delta CT = \Delta CT$ of target genes – ΔCT of HPRT1).

Western blot analysis

Western blot analysis was done with antibodies against FOXM1 (ab207298; CAT#: 13147-1-AP, Proteintech), MAT α 2 (55309-1-AP), MAT2 β (BNP1-82797), α -SMA (ab5831), COL1A1 (ab270993), β -actin (ab8226), F4/80 (ab300421), SMAD3 (ab52903), tumor necrosis factor alpha (TNF- α , ab183218), tubulin (ab18251) and interleukin 6 (IL-6, ab259341). The membranes were incubated with secondary antibody (mouse anti-rabbit IgG, Cell Signaling, #7074, USA) for 40 min at room temperature. Membranes were stripped and re-probed with antibodies against β -actin or histone H3 as housekeeping control or CD9 as EVs control. A chemiluminescence system (Millipore Corporation, Billerica, MA, USA) was used for signal detection. All results were quantified by ImageJ software (versions 1.51 and 1.54j). Statistical significance was defined as $p < 0.05$.


Morphological and immunohistochemical analysis

All human and mouse liver tissues were embedded in paraffin, sectioned, and stained with hematoxylin & eosin (H&E), Sirius red, and F4/80. Five μ M paraffin sections of the liver tissue samples were used for IHC staining. Slides were immunostained with antibodies to FOXM1, MAT α 2, MAT2 β , COL1A1, EMR1 (F4/80), α -SMA, Keratin 19 (CK19, ab52625), and IgG according to an IHC detection kit (ab64264). All sections were counterstained with hematoxylin for 30 s and were observed under Digital Inverted Fluorescence Microscope (ThermoFisher, AMF4300). No staining occurred with normal mouse IgG. For every slide, 10 representative fields were captured randomly and analyzed by Image-Pro Plus v6.0 software.

Promoter analysis

The -1329/+60 PCR product representing the MAT2A 5'-flanking region was cloned in the sense orientation upstream of the luciferase coding sequence of the pGL3-basic vector (Promega)⁴³. To produce 5'-deletion constructs, MAT2A promoter was digested with NheI and AflII to produce a -939 to +60 deletion, NheI and EcoRV to produce a -571 to +60 deletion, and NheI and ApaI (-47 to +60 deletion. -271/+60 bp deletion was produced using forward primer 5'-CATCAAA-CAGGAAGAGCAATCC-3' (-250 to -271 bp relative to transcription start site) and reverse primer 5'-AGCTGCGGACAGCGTTCTACTCG-3' (+39 to +60 bp relative to transcription start site). Mutagenesis of the

MAT2A promoter FOX binding sites were performed as follows: 5'-CTATAAA-3' (-16 to -22) was changed to 5'-CTATCAA-3' using forward primer 5'-GGCGCTGCTCTATCAATACCGGGCC-3' (-7 to -30 bp relative to transcription start site); 5'-CATCAAACA-3' (-264 to -272) was changed to 5'-CATCCAACA-3' using forward primer 5'-TTTCTCCACATCCAACAAGGAAGAGC-3' (-255 to -281). A -1319/+3 5'-flanking region of the human MAT2B was cloned into the SmaI site of pGL-3 basic vector⁴³. MAT2B promoter was subcloned with forward primers from -990 to -967, -713 to -688, and -250 to -225, and reverse primer was +3 to -20 to generate deletion constructs -990/+3, -713/+3, and -250/+3 MAT2B-LUC, respectively. All sequences are relative to the ATG start codon. Mutagenesis of the MAT2B promoter FOX binding site was performed as follows: 5'-CAAATA-3' was changed to 5'-CAACTA-3' (-140 to -145) using forward primer 5'-AATAAAAAGCACTCAACTAAAATCTCCGAAAC-3' (-127 to -158) with QuikChange multisite-Directed mutagenesis kit (#200515-5) from Agilent Technologies (Carpinteria, CA). The mutant strand synthesis reaction consisted of an initial denaturation at 95 °C for 30 s followed by 16 cycles at 95 °C for 30 s, annealing at 55 °C for one minute and extension at 68 °C for one minute/kb of plasmid length using the PfuUltra HF DNA polymerase. DpnI digestion of the amplified PCR products and transformation of XL10-gold ultracompetent cells were done in accordance with their suggested protocol (Agilent Technologies). The human 1.4 kb FOXM1 promoter was purchased from GeneCopoeia (Rockville, MD). FOXM1 promoter was subcloned with forward primers from -1304 to -1282 and -123 to -102, and reverse primer was +89 to +107 to generate deletion constructs -1304/+107, and -123/+107 FOXM1-LUC, respectively. Mutagenesis of the FOX binding sites in the FOXM1 promoter were performed as follows: 5'-TGTTTG-3' (-1022 to -1027) was changed to 5'-GGTTTG-3' using forward primer 5'-GCAATAATTCACATTGGTTGTTTGGAGAC-3' (-1012 to -1043 bp relative to transcription start site), and 5'-TGTTTA-3' (-732 to -737) was changed to 5'-TGTTGA-3' using forward primer 5'-GCCCACATTGTTGATTGATTAATAATGTC-3' (-717 to -751), with QuikChange multisite-Directed mutagenesis kit (Agilent Technologies, Inc. Santa Clara, CA). Plasmids were transfected into cells using Lipofectamine 2000 reagent (Invitrogen, #11668019, MA). Promoter constructs and pGL3/pLuc-MCS/PEZ/SV40 (1 μ g) were then transfected into LX-2 and primary cholangiocytes using JetPRIME transfection reagent (Polyplus Transfection, #101000027, USA). Luciferase assays were performed by the Dual Luciferase Reporter Assay System (Promega, #E190, USA) 24 h after transfection.



Isolation of extracellular vesicles (EVs) and characterization

Since FOXM1, MAT α 2 and MAT2 β expression increased dramatically in hepatocytes, HSCs, and KCs after BDL, we isolated EVs from these cells after BDL and used them to treat other liver cell types. We used commercial kits (Thermo Fisher cat# 4484450, 4478360; SBI cat# EQ806A-1) for EVs isolation. Briefly, serum-free media was collected

and centrifuged at 2000 g for 30 min to remove the cell debris. Then we further concentrated the 150 ml supernatant media to 1 ml with MilliporeSigma UFC701008 Centricon Plus-70 Centrifugal Filter (100 kD)⁴⁴. The concentrated medium was then processed with the SBI kit according to the provided protocol. The concentration and size distribution of EVs were assessed using Nanoparticle Tracking Analysis

Fig. 7 | Roles of FOXM1, MAT2A and MAT2B in transforming growth factor (TGF)- β 1 signaling in LX-2 cells and LPS effects in macrophages, and their presence in EVs. **a** Time courses of protein expression of FOXM1, MAT α 2, MAT2 β , SMAD3, α -SMA, and COL1A1 after TGF- β 1 treatment in LX-2 cells. **b** FOXM1, MAT α 2, MAT2 β , SMAD3, α -SMA and COL1A1 protein levels after siRNA knockdown of FOXM1, MAT2A, or MAT2B in LX-2 cells after 24 h. **c** Protein levels of FOXM1, MAT α 2, MAT2 β , SMAD3, α -SMA, and COL1A1 after FOXM1 overexpression with or without MAT2A or MAT2B siRNA knockdown and TGF- β 1 treatment (20 ng/ml) for

24 h in LX-2 cells. **d** Effect of LPS on protein expression of FOXM1, MAT α 2, MAT2 β , TNF- α , and IL-6 with or without siRNA knockdown of FOXM1, MAT2A or MAT2B in RAW 264.7 cells for 24 h. **e** Effects of LPS on protein expression of FOXM1, MAT α 2, MAT2 β , TNF- α , and IL-6 with FOXM1 overexpression and MAT2A or MAT2B siRNA treatment for 24 h in RAW 264.7 cells (left panel) and KCs isolated from Flox control mice (right panel). Densitometry values for protein levels are summarized in Supplementary Fig. 12e, f and Supplementary Fig. 13a–d. $n = 3$ independent experiments. Source data are provided as a Source Data file.

(NTA) via NanoSight NS300. Validation of EVs was performed through western blot analysis employing EVs markers⁴⁵.

We used 10 μ g of EVs to treat hepatocytes, HSCs, and KCs. HSCs from *Foxm1*^{HSC-/-} were treated with EVs from hepatocytes of *Foxm1*^{Hep-/-} and Flox. Hepatocytes from *Foxm1*^{Hep-/-} were treated with EVs from HSCs of *Foxm1*^{HSC-/-} and Flox. Hepatocytes from *Foxm1*^{Hep-/-} and HSCs from *Foxm1*^{HSC-/-} were treated with EVs from Flox and *Foxm1*^{KC-/-}. Expression of FOXM1, MAT α 2, and MAT2 β were measured by western blot in HSCs, hepatocytes, and KCs.

ChIP and sequential-ChIP (Seq-ChIP)

LX-2 cells were crosslinked with formaldehyde to bind the proteins to the DNA. The fragmentation of DNA was made by cell sonication (shearing of DNA into small fragments ranging from 50 to 500 bp). Immunoprecipitation (IP) using FOXM1, MAT α 2, and MAT2 β and IgG antibodies enriches the fragments bound by the protein. Then, crosslink reversal frees the DNA fragments for further processing. ChIP and Seq-ChIP were performed using a EpiTect ChIP OneDay kit (Qiagen, Germantown, MD) in accordance with the kit instructions. For the FOX element of the human *FOXM1* promoter, DNA immunoprecipitation (IP) was performed using antibodies against MAT α 2, MAT2 β and FOXM1. IgG was used for control. This was followed by a second round of IP using antibodies against MAT α 2, MAT2 β and FOXM1. The purified DNA was detected by PCR analysis. PCR primers for promoter regions containing FOX binding sites were FOXM1 - forward 5'-CATTTGTTTGTGTTTGGAGACGGTGTC-3' (-1006 to -1031) and reverse 5'-GGAAGAGGGGCACAGACATTTAATC-3' (-703 to -728) (GenBank® accession no. NM-001243088). All PCR products were electrophoresed on 2% agarose gel. The PCR protocol involved initial denaturation at 94 °C for 3 min and 25 cycles at 94 °C for 30 s, followed by annealing and extension at 65 °C for 90 s using the Advantage GC 2 PCR kit (Clontech, Mountain View, CA).

For ChIP-qPCR assays, chromatin was prepared from LX-2 cells treated with scrambled control, siRNAs of *MAT2A*, *MAT2B* and *FOXM1*, overexpression of *MAT2A*, *MAT2B* and *FOXM1*, or empty vector. Chromatin was enzymatically sheared and immunoprecipitated with anti-MAT α 2, anti-MAT2 β and anti-FOXM1 using Pierce™ Magnetic ChIP Kit (Cat#: 26157, ThermoFisher Scientific) in accordance with the kit's instructions. Rabbit IgG was used as a mock antibody for negative control. Immunoprecipitated chromatin was subjected to real-time qPCR with the SYBR Premix DimerEraser (RR091A, Takara). Two ChIP-qPCR primer pairs (forward primer: 5'-CATTTGTTTGTGTTTGGAGACGGTGTC-3' (-1006 to -1031) and reverse primer: 5'-ATAAACAAATGTGGGCTGGGCATAG-3' (-730 to -755)) overlap two FOX binding sites of the human *FOXM1* promoter region. Samples were run in triplicates, and data from MAT α 2, MAT2 β and FOXM1 IP, and control IP were presented as enrichment relative to input DNA. ChIP-qPCR was repeated triplicates to confirm the reproducibility of results. The quality of chromatin enzymatically sheared was assessed using agarose gel electrophoresis. The percent input is used to normalize ChIP-qPCR data. 1% of starting chromatin is used as input. ChIP-qPCR data is normalized for both background levels and input chromatin going into the ChIP. Pierce™ Magnetic ChIP Kit (Cat#: 26157).

Electrophoretic mobility shift assay (EMSA)

In 10 cm dishes, LX-2 cells were transfected with scrambled control, siRNA (si) against *FOXM1*, *MAT2A*, or *MAT2B*, empty vector (EV), *FOXM1* OV, *MAT2A* OV, or *MAT2B* OV for 48 h. LX-2 cells were grown to 70–80% and after removing the medium, cells were washed twice with ice-cold PBS and scraped into a 15 mL conical tube and centrifuged at 1000 rpm for 5 min. The nuclear proteins from LX-2 cells were isolated using the Nuclear-Extraction kit (Abcam, ab113473). Double FOX binding sites (5'-ACATTTGTTTGTGTTTACATTTGTTTATTGA-3') were used for gel shift and super shift probe. EMSA assays were done by following the EMSA Kit (ThermoFisher Scientific, E33075). The shift bands were detected from the gel images with three biological replicates. The shifted bands were compared with that of the non-shifted band in each lane^{46,47}.

MTT and migration assays


For MTT assays, LX-2 Cells were cultured at 1×10^6 cells per ml in a transparent plate and rinsed twice with PBS. 50 μ L serum-free medium and 50 μ L MTT reagent was added according to manuscript (ab211091, USA). After 3 h of incubation at 37 °C, 150 μ L of MTT solvent was added to each well. Plate was wrapped in foil and shaken for 15 min on an orbital shaker. Data was read at OD = 590 nm. For migration assays, LX-2 cells (1×10^5) were seeded into transwell inserts (8- μ m pore size, BD Falcon). After 24 h of culture for the migration assays, the wells were stained with crystal violet (Beyotime, C0121). Migrated cells number was quantified using the ImageJ software.

Immunofluorescence staining

Primary HSCs and LX-2 cells were plated on 6-well plates containing coverslips. Cells were fixed with 4% paraformaldehyde for 30 min at room temperature and ice-cold methanol for 15 min. Cells were then blocked by incubation in PBS with 0.05% TWEEN® 20 (PBST, Sigma, P3563) containing 10% goat serum and 3% BSA for 45 min. Samples were incubated with FOXM1, MAT α 2, and MAT2 β antibodies at 250-time dilution (1:250) in PBS for 1 h at 37 °C and incubated with fluorescent secondary antibodies (Invitrogen, Waltham, MA) for 3 h. Negative control was used with IgG antibody (Abcam, ab171870; Rabbit). VECTASHIELD mounting medium (Sigma, #DUO82040) containing DAPI was used to mount slides. EVOS™ FL and EVOS™ FL color Imaging systems (ThermoFisher Scientific, AMF4300) were used to capture images. Photoshop (version 23.5.2) overlay method was used to contrast and overlay images.

FOXM1-MAT α 2-MAT2 β interactions

40 μ L of A/G beads (Cat#: SC-2003, Santa Cruz Biotechnology), 500 μ L IP buffer (150 mM NaCl, 50 mM Tris-HCl PH7.6, 1 mM EDTA PH7.0, 1 mM EGTA7.4, 25 mM NaF, 1% NP-40), and 2 μ g of MAT α 2, MAT2 β or FOXM1 antibody were mixed and rotated at 4 °C for one hour. The beads were washed 6 times with 500 μ L IP buffer. For recombinant proteins (FOXM1, MAT α 2, and MAT2 β) interactions, after the final wash with 500 μ L of IP buffer above, 1 μ g of recombinant protein was added. For the extracted proteins, 500 μ L of IP buffer and 500 μ g lysates were needed. 500 μ L of IP buffer and 0.5 μ L of rabbit IgG were mixed as control. All the reaction tubes were rotated at 4 °C overnight.



Then the beads were washed 6 times with 500 μ L IP buffer. After the last wash buffer was removed and beads were boiled in 2 $\times$ SDS sample buffer for 10 min at 95 $^{\circ}$ C, and proteins were separated on 10% SDS-PAGE followed by Immunoblot analysis for MATα2, MAT2β and FOXM1.

Enzyme-linked immunosorbent assay (ELISA)

Raw 264.7 cells were cultivated in high-glucose DMEM containing 10% FBS, 100 U/mL penicillin, and 100 μ g/mL streptomycin at 37 $^{\circ}$ C in a humidified incubator containing 5% CO₂. After overnight culture in a 96-well plate (2 $\times$ 10⁴ cells/well, 200 μ L medium/well), cells were

Fig. 8 | FOXM1, MAT α 2, MAT2 β are secreted in EVs and exchanged between hepatocytes, HSCs, and KCs. **a** Following BDL and culture of hepatocytes from flox mice and *Foxm1*^{flp/+}, EVs were extracted from the medium and used to treat HSCs from *Foxm1*^{flp/+}. **b** Following BDL and culture of HSCs from flox mice and *Foxm1*^{flp/+}, EVs were extracted from the medium and used to treat hepatocytes from *Foxm1*^{flp/+}. **c, d** Following BDL and culture of KCs from flox mice and *Foxm1*^{flp/+}, EVs were extracted from the medium and used to treat (c) HSCs from *Foxm1*^{flp/+} or (d) hepatocytes from *Foxm1*^{flp/+}. **e** EVs extracted from hepatocytes of Flox and

Foxm1^{flp/+} after BDL were used to treat KCs from *Foxm1*^{flp/+} and (f) EVs extracted from HSCs of Flox and *Foxm1*^{flp/+} after BDL were used to treat KCs from *Foxm1*^{flp/+}. All EV treatments were for 24 h after which protein expression of FOXM1, MAT α 2 and MAT2 β were measured in cell lysates by western blotting. Densitometry values for protein levels are summarized in Supplementary Fig. 14a–f, *n* = 3 independent experiments (g) Summary of key findings showing the FOXM1/MAT2A/MAT2B axis in the different liver cell types driving liver inflammation and fibrosis. Source data are provided as a Source Data file.

transfected with siRNAs of scrambled, FOXM1, MAT2A and MAT2B for 8 h and treated with LPS (*Escherichia coli*, Sigma-Aldrich L4130 O111: B4) at 1 μ g/ml for an additional 16 h. The culture supernatant from each well was collected at the end of scheduled experiments and used to measure TNF- α (KE10002) and IL-6 (KE10091, proteintech, Rosemont, IL, USA) concentration by ELISA according to the manufacturer's instructions, and the absorbance was measured at 450 nm and 630 nm, respectively, using a microplate reader.

Statistical analysis

All sample data were presented as mean $\pm$ standard error of the mean (SEM). Sample data statistical analysis was used Student *t*-test and one-way ANOVA, followed by Fisher's test for multiple comparisons. Chi-square test was used to analyze mRNA levels of *FOXM1*, *MAT2A* or *MAT2B* and clinicopathological features in liver cirrhosis. Pearson correlation was used to measure the strength of the linear relationship between *FOXM1* and *MAT2A*, *FOXM1* and *MAT2B*, *MAT2A* and *MAT2B* in human liver cirrhosis tissues. All experiments were repeated at least three times, and *p* < 0.05 was considered statistical significance. Excel (16.54) and Graphpad Prism 9.0.0 were used for calculations.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

All data supporting the findings described in this manuscript are available in the article and in the Supplementary Information and from the corresponding author upon request. Source data are provided with this paper.

References

- Friedman, S. L. Liver fibrosis – from bench to bedside. *J. Hepatol.* **38**, S38–S53 (2003).
- Li, Y. et al. Reciprocal regulation between forkhead box M1/NF- κ B and methionine adenosyltransferase 1A drives liver cancer. *Hepatology* **72**, 1682–1700 (2020).
- Kurahashi, T. et al. Forkhead box M1 transcription factor drives liver inflammation linking to hepatocarcinogenesis in mice. *Cell. Mol. Gastroenterol. Hepatol.* **9**, 425–446 (2020).
- Sun, W. et al. ALKBH5 promotes lung fibroblast activation and silica-induced pulmonary fibrosis through miR-320a-3p and FOXM1. *Cell. Mol. Biol. Lett.* **27**, 26 (2022).
- Filliol, A. & Schwabe, R. F. FoxM1 induces CCL2 secretion from hepatocytes triggering hepatic inflammation, injury, fibrosis, and liver cancer. *Cell. Mol. Gastroenterol. Hepatol.* **9**, 555–556 (2020).
- Wang, Y., Zhou, Q., Tang, R., Huang, Y. & He, T. FoxM1 inhibition ameliorates renal interstitial fibrosis by decreasing extracellular matrix and epithelial-mesenchymal transition. *J. Pharmacol. Sci.* **143**, 281–289 (2020).
- Gormally, M. V. et al. Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition. *Nat. Commun.* **5**, 5165 (2014).
- Lan, C. et al. Forkhead domain inhibitor-6 suppresses corneal neovascularization and subsequent fibrosis after alkali burn in rats. *Invest. Ophthalmol. Vis. Sci.* **63**, 14 (2022).
- Lan, C. et al. Forkhead domain inhibitory-6 attenuates sub-conjunctival fibrosis in rabbit model with trabeculectomy. *Exp. Eye. Res.* **210**, 108725 (2021).
- Murray, B., Barbier-Torres, L., Fan, W., Mato, J. M. & Lu, S. C. Methionine adenosyltransferases in liver cancer. *World J. Gastroenterol.* **25**, 4300–4319 (2019).
- Mato, J. M. & Lu, S. C. Role of S-adenosyl-L-methionine in liver health and injury. *Hepatology* **45**, 1306–1312 (2007).
- Ramani, K., Donoyan, S., Tomasi, M. L. & Park, S. Role of methionine adenosyltransferase α 2 and β phosphorylation and stabilization in human hepatic stellate cell trans-differentiation. *J. Cell. Physiol.* **230**, 1075–1085 (2015).
- Hu, X. & Zhou, Y. Curcumin reduces methionine adenosyltransferase 2B expression by interrupting phosphorylation of p38 MAPK in hepatic stellate cells. *Eur. J. Pharmacol.* **886**, 173424 (2020).
- Wang, K. et al. TGF- β 1/p65/MAT2A pathway regulates liver fibrogenesis via intracellular SAM. *EBioMedicine* **42**, 458–469 (2019).
- Luedde, T., Kaplowitz, N. & Schwabe, R. F. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. *Gastroenterology* **147**, 765–783 (2014).
- Koyama, Y. & Brenner, D. A. Liver inflammation and fibrosis. *J. Clin. Invest.* **127**, 55–64 (2017).
- Dewidar, B., Meyer, C., Dooley, S. & Meindl-Beinker, A. N. TGF- β in hepatic stellate cell activation and liver fibrogenesis-updated 2019. *Cells* **8**, 1419 (2019).
- Zehender, A. et al. TGF β promotes fibrosis by MYST1-dependent epigenetic regulation of autophagy. *Nat. Commun.* **12**, 4404 (2021).
- Binatti, E., Gerussi, A., Barisani, D. & Invernizzi, P. The role of macrophages in liver fibrosis: new therapeutic opportunities. *Int. J. Mol. Sci.* **23**, 6649 (2022).
- Yamaguchi, M., Hashimoto, K., Jijiwa, M. & Murata, T. The inflammatory macrophages repress the growth of bone metastatic human prostate cancer cells via TNF- α and IL-6 signaling: involvement of cell signaling regulator regucalcin. *Cell. Signal.* **107**, 110663 (2023).
- Rho, H., Terry, A. R., Chronis, C. & Hay, N. Hexokinase 2-mediated gene expression via histone lactylation is required for hepatic stellate cell activation and liver fibrosis. *Cell. Metab.* **35**, 1406–1423 (2023).
- Zhang, Z., Li, M., Sun, T., Zhang, Z. & Liu, C. FOXM1: functional roles of FOXM1 in non-malignant diseases. *Biomolecules* **13**, 857 (2023).
- Hu, G. et al. FOXM1 promotes hepatocellular carcinoma progression by regulating KIF4A expression. *J. Exp. Clin. Cancer Res.* **38**, 188 (2019).
- Khan, M. A., Khan, P., Ahmad, A., Fatima, M. & Nasser, M. W. FOXM1: a small fox that makes more tracks for cancer progression and metastasis. *Semin. Cancer Biol.* **92**, 1–15 (2023).
- Liang, S. K. et al. FOXM1 is required for small cell lung cancer tumorigenesis and associated with poor clinical prognosis. *Oncogene* **40**, 4847–4858 (2021).

26. Wang, K. et al. Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression. *J. Exp. Clin. Cancer Res.* **41**, 289 (2022).
27. Tomasi, M. L. et al. Methionine adenosyltransferase $\alpha 2$ sumoylation positively regulate Bcl-2 expression in human colon and liver cancer cells. *Oncotarget* **6**, 37706–37723 (2015).
28. Liu, T. et al. Mechanisms of MAFG dysregulation in cholestatic liver injury and development of liver cancer. *Gastroenterology* **155**, 557–571 (2018).
29. Tomasi, M. L. et al. S-adenosylmethionine and methylthioadenosine inhibit cancer metastasis by targeting microRNA 34a/b-methionine adenosyltransferase 2A/2B axis. *Oncotarget* **8**, 78851–78869 (2017).
30. Gartel, A. L. FOXM1 in cancer: interactions and vulnerabilities. *Cancer Res.* **77**, 3135–3139 (2017).
31. Liu, Q. et al. The X protein of hepatitis B virus inhibits apoptosis in hepatoma cells through enhancing the methionine adenosyltransferase 2A gene expression and reducing S-adenosylmethionine production. *J. Biol. Chem.* **286**, 17168–17180 (2011).
32. Wree, A., Mehal, W. Z. & Feldstein, A. E. Targeting cell death and sterile inflammation loop for the treatment of nonalcoholic steatohepatitis. *Semin. Liver. Dis.* **36**, 27–36 (2016).
33. Pradere, J. P. et al. Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. *Hepatology* **58**, 1461–1473 (2013).
34. Kalluri, R. & LeBleu, V. S. The biology, function, and biomedical applications of exosomes. *Science* **367**, eaau6977 (2020).
35. Luo, Z. et al. CRIG(+) Macrophages prevent gut microbial DNA-containing extracellular vesicle-induced tissue inflammation and insulin resistance. *Gastroenterology* **160**, 863–874 (2021).
36. Isaac, R., Reis, F. C. G., Ying, W. & Olefsky, J. M. Exosomes as mediators of intercellular crosstalk in metabolism. *Cell. Metab.* **33**, 1744–1762 (2021).
37. Mathieu, M., Martin-Jaular, L., Lavie, G. & Théry, C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. *Nat. Cell. Biol.* **21**, 9–17 (2019).
38. Cho, Y. E., Song, B. J., Akbar, M. & Baek, M. C. Extracellular vesicles as potential biomarkers for alcohol- and drug-induced liver injury and their therapeutic applications. *Pharmacol. Ther.* **187**, 180–194 (2018).
39. Hernández, A. et al. Chemical hypoxia induces pro-inflammatory signals in fat-laden hepatocytes and contributes to cellular cross-talk with Kupffer cells through extracellular vesicles. *Biochim. Biophys. Acta Mol. Basis. Dis.* **1866**, 165753 (2020).
40. Tabibian, J. H., Masyuk, A. I., Masyuk, T. V., O'Hara, S. P. & LaRusso, N. F. Physiology of cholangiocytes. *Compr. Physiol.* **3**, 541–565 (2013).
41. Perea, L. et al. Pentraxin-3 modulates lipopolysaccharide-induced inflammatory response and attenuates liver injury. *Hepatology* **66**, 953–968 (2017).
42. Tsochatzis, E. et al. Collagen proportionate area is superior to other histological methods for sub-classifying cirrhosis and determining prognosis. *J. Hepatol.* **60**, 948–954 (2014).
43. Yang, H. et al. Expression pattern, regulation, and functions of methionine adenosyltransferase 2beta splicing variants in hepatoma cells. *Gastroenterology* **134**, 281–291 (2008).
44. Chhoy, P., Brown, C. W., Amante, J. J. & Mercurio, A. M. Protocol for the separation of extracellular vesicles by ultracentrifugation from in vitro cell culture models. *Star. Protoc.* **2**, 100303 (2021).
45. Liu, J. et al. Extracellular vesicles-encapsulated let-7i shed from bone mesenchymal stem cells suppress lung cancer via KDM3A/DCLK1/FXYD3 axis. *J. Cell. Mol. Med.* **25**, 1911–1926 (2021).
46. Yang, B. et al. CSNK2A1-mediated MAX phosphorylation upregulates HMGB1 and IL-6 expression in cholangiocarcinoma progression. *Hepatol. Commun.* **7**, e00144 (2023).
47. Lu, L. et al. Deregulated 14-3-3 ζ and methionine adenosyltransferase $\alpha 1$ interplay promotes liver cancer tumorigenesis in mice and humans. *Oncogene* **40**, 5866–5879 (2021).

Acknowledgements

This work was financially supported by NIH grant P01CA233452 (S.C. Lu, H. Yang, E. Seki), Plan Nacional of I + D SAF2017-88041-R (J.M. Mato), National Natural Science Foundation of China 82070632 (Liu T.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author contributions

B.Y., L.L., T.X., H.Y., J.H., W.F., T.T., D.C., J.Z. and H. P. performed the experiments and analyzed the data. B.Y., L.L., T.X. and H.Y. reviewed the literature, drafted the manuscript. L.L. and T.L. collected the clinic sample and data. J. W. performed cell culture, analysis, and interpretation. N. M. and M.L.T. bred the mice. L.B.-T., J.M.M., X.Y., J.C., S.S. and K.R. provided critical reading and editing of the manuscript. V.K. provided the Foxm1 flox mice. E.S. provided the L-rat-Cre mice and critical reading of the manuscript. H.Y. supervised the experiments. S.C.L. obtained funding, conceptualized the experiments, provided overall direction, and edited the manuscript. All authors have read and approved the final manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41467-024-52527-8>.

Correspondence and requests for materials should be addressed to Heping Yang or Shelly C. Lu.

Peer review information *Nature Communications* thanks Chang Liu, and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. A peer review file is available.

Reprints and permissions information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

© The Author(s) 2024

¹Karsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical Center, LA, Los Angeles, CA 90048, USA. ²Department of Geriatric Endocrinology and Metabolism, Guangxi Key Laboratory of Precision Medicine in Cardio-cerebrovascular Diseases Control and Prevention, Guangxi Clinical Research Center for Cardio-cerebrovascular Diseases, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, China. ³Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China. ⁴Department of Pharmacy, The Third Hospital of Changsha, Changsha, Hunan 410015, China. ⁵Department of Biomedical Sciences, CSMC LA, Los Angeles, CA 90048, USA. ⁶Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. ⁷CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Technology, Park of Bizkaia, 48120 Derio, Bizkaia, Spain. ⁸Department of Gastroenterology, Xiangya Hospital, Key Laboratory of Cancer proteomics of Chinese Ministry of Health, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China. ⁹Phoenix Children's Research Institute, Department of Child Health, University of Arizona College of Medicine, Phoenix, AZ 85004, USA. ¹⁰Division of Neonatology, Phoenix Children's Hospital, Phoenix, AZ 85016, USA. ¹¹Department of Society and Genetics, UCLA LA, Los Angeles, CA 92620, USA. ¹²These authors contributed equally: Bing Yang, Liqing Lu, Ting Xiong. ✉ e-mail: Heping.yang@cshs.org; shelly.lu@cshs.org